Access to α-all-carbon quaternary amides through the hydroamidation of allenes using DIBAL-H and isocyanates

Kyeongmin Lee, Soohong Cho, Seeun Lim and Yunmi Lee*

Department of Chemistry, Kwangwoon University, Seoul 01897, Republic of Korea

Supplementary Information

Table of Contents

1. General information	S2
2. Preparation of substrates	S2
3. Cu-Catalyzed hydroalumination of allene 1a with diisobutylaluminum hydride	S7
4. General procedure for the synthesis of β , γ -unsaturated α -quaternary amides	S9
5. Characterization data for all products	S9
6. Procedure for gram-scale reaction	S28
7. Synthetic applications	S28
8. Copies of ¹ H and ¹³ C NMR spectra for all products	S34
9. 2D-NOESY proton NMR spectra of compound 4xa-1 , 4xa-2 and ¹ H NOESY correlations	S99

1. General information

Infrared (IR) spectra were recorded on a ABB MB3000 FT-IR spectrophotometer, and are quoted in wavenumbers (cm⁻¹). Bands are characterized as strong (s), medium (m), and weak (w). ¹H NMR spectra were recorded a JEOL JNM-AL400 (400 MHz) spectrometer. Chemical shifts are reported in ppm from tetramethylsilane, with the solvent resonance as the internal standard (CDCl₃: δ 7.27 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet), coupling constants (Hz), and integration. ¹³C NMR spectra were recorded on a JEOL JNM-AL400 (100 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl₃: δ 77.00 ppm). ¹⁹F NMR spectra were recorded on a Spinsolve 80 (75.2 Hz) spectrometer and reported in ppm from CFCl3 and are uncorrected. High-resolution mass spectra (HRMS) were performed at the Korea Basic Science Institute for technical assistance using an electron ionization (EI) or an electrospray ionization (ESI) time-of-flight mass spectrometer.

Unless otherwise noted, all reactions were carried out with distilled solvents under an atmosphere of dry N_2 in oven-dried (130 °C) glassware. Tetrahydrofuran was purified by distillation from Na immediately prior to use. DIBAL-H was purchased from Sigma-Aldrich Corporation and used as received. A variety of isocyanates were purchased from TCI, Alfa Aesar, Sigma-Aldrich Corporation and used as received. All work-up and purification procedures were carried out with reagent grade solvents in air. The NHC-CuCl complex was synthesized according to previously reported experimental procedures.¹

2. Preparation of substrates

- (1) 1,1-Disubsitutited allenes **1a-1m** were prepared according to reported experimental procedures.²
- Representative experimental procedure for the synthesis of 1,1-disubsitutited allene:



⁽¹⁾ W.-J. Yoo, T. V. Q. Nguyen and S. Kobayashi, Angew. Chem., Int. Ed., 2014, 53, 10213–10217.

^{(2) (}a) S. Lee, S. Lee and Y. Lee, *Org. Lett.*, 2020, **22**, 5806–5810; (b) A. Boreux, K. Indukuri, F. Gagosz and O. Riant, *ACS Catal.*, 2017, **7**, 8200–8204; (c) V. Gobé and X. Guinchard, *Chem. Eur. J.*, 2015, **21**, 8511–8520; (c) G. Mentink, J. H. Van Maarseveen and H. Hiemstra, *Org. Lett.*, 2002, **4**, 3497–3500.



1-Chloro-2-(3-methylpenta-3,4-dien-1-yl)benzene (1i). MeMgCl (3.0 M in THF, 1.50 mL, 4.50 mmol) was added dropwise to a solution of CuCN (403 mg, 4.50 mmol) and LiCl (382 mg, 9.00 mmol) in THF (13 mL) using a syringe at 22 °C

under N₂. The solution was stirred for 0.5 h and allowed to cool to 0 °C in an ice bath. Then, a solution of 5-(2-chlorophenyl)pent-2-yn-1-yl 4-methylbenzenesulfonate (523 mg, 1.50 mmol) was added to THF (2 mL). The mixture was allowed to warm to room temperature and stirred for 1 h. Afterward, the resulting solution was allowed to cool to 0 °C, quenched with water (10 mL), and washed with diethyl ether (20 mL × 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated. The crude product was purified using silica gel column chromatography (100% hexanes), and the desired allene **1i** (275 mg, 1.43 mmol, 95%) was obtained as a colorless oil. **IR** (neat): 2978 (m), 2932 (m), 2862 (m), 1960 (m), 1744 (m), 1705 (s), 1443 (m), 1458 (m), 1049 (m), 1041 (m), 849 (s), 748 (s), 679 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.35 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.24-7.13 (m, 3H), 4.64 (sext, *J* = 3.0 Hz, 2H), 2.87 (t, *J* = 8.0 Hz, 2H), 2.27-2.21 (m, 2H), 1.75 (t, *J* = 3.0 Hz, 3H); ¹³C{¹**H**} **NMR** (CDCl₃, 100 MHz): δ 206.1, 139.7, 133.9, 130.3, 129.4, 127.3, 126.7, 97.9, 74.7, 33.4, 31.8, 18.8; **HRMS** (EI) *m/z*: [M]⁺ Calcd for C₁₂H₁₃Cl 192.0706, Found 192.0700.



1-Bromo-2-(3-methylpenta-3,4-dien-1-yl)benzene (1j). Compound **1j** was synthesized from 5-(2-bromophenyl)pent-2-yn-1-yl 4-methylbenzenesulfonate (2.00 g, 5.09 mmol) in 90% yield (1.09 g, 4.58 mmol) as a colorless oil. The crude

product was purified using silica gel column chromatography (100% hexanes). **IR** (neat): 2932 (m), 2361 (m), 2330 (m), 1960 (m), 1798 (m), 1744 (m), 1705 (m), 1443 (m), 1026 (m), 849 (s), 741 (s), 656 (m), 602 (m) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.53 (d, *J* = 7.5 Hz, 1H), 7.26-7.21 (m, 2H), 7.09-7.03 (m, 1H), 4.65 (sext, *J* = 3.1 Hz, 2H), 2.87 (t, *J* = 8.2 Hz, 2H), 2.27-2.21 (m, 2H), 1.76 (t, *J* = 3.0 Hz, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 206.2, 141.4, 132.7, 130.3, 127.5, 127.4, 124.4, 97.9, 74.7, 34.3, 33.5, 18.8; **HRMS** (EI) *m/z*: [M]⁺ Calcd for C₁₂H₁₃Br 236.0201, Found 236.0193.

(2) 1,1,3-Trisubstituted allenes **1n-1x** were prepared according to reported experimental procedures.³

• Experimental procedure for the synthesis of (2-cyclohexylidenevinyl)benzene (10):

^{(3) (}a) X. D. Vial, J. L. Mascarenas and M. I. Gulias, *Org. Lett.*, 2021, **23**, 5323–5328; (b) J. Eshon, C. R. Landis and J. M. Schomaker, *J. Org. Chem.*, 2017, **82**, 9270–9278; (c) C.-M. Ting, Y.-L. Hsu and R.-S. Liu, *Chem. Commun.*, 2012, **48**, 6577–6579.



n-BuLi (2.5 M in hexanes, 3.14 mL, 7.84 mmol) was added to a solution of Cp₂ZrCl₂ (2.29 g, 7.84 mmol) in THF (37.2 mL) at -78 °C (dry ice/acetone bath) under N₂ flow. After stirring for 1 h at the same temperature, a solution of ((1-methoxycyclohexyl)ethynyl)benzene (S1, 1.05 g, 4.90 mmol) in THF (2 mL) was added, and the mixture was allowed to warm to room temperature. The reaction mixture was stirred for 3 h and quenched by adding an aqueous solution of 1 N HCl (3 mL), followed by washing with ethyl ether (20 mL × 3). The organic layers were combined, washed with a saturated aqueous solution of NaHCO₃ (20 mL), dried over MgSO₄, filtered, and concentrated. The crude product was purified using silica gel column chromatography (100% hexanes), and the desired allene **10** (704 mg, 3.82 mmol, 78%) was obtained as a colorless oil. This compound has been previously reported, and our experimental spectral data match the previously reported data.⁴ ¹H NMR (CDCl₃, 400 MHz): δ 7.32-7.31 (m, 4H), 7.22-7.17 (m, 1H), 6.03-6.02 (m, 1H), 2.32-2.28 (m, 2H), 2.26-2.21 (m, 2H), 1.74-1.58 (m, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 199.6, 136.1, 128.5, 126.5, 126.3, 106.5, 92.3, 31.3, 27.7, 26.1.

• Representative experimental procedure for the synthesis of 1,1,3-trisubsitutited allene:



(3-Methylbuta-1,2-dien-1-yl)benzene (1n). MeMgCI (3.0 M in THF, 3.47 mL, 10.4 mmol) was added to a solution of Cul (3.05 g, 16.0 mmol) and LiBr (1.83 g, 21.1 mmol) in THF (24.5 mL) at 0 °C (ice bath) under N₂. The solution was stirred for 1 h before adding a solution of 1-phenylbut-2-yn-1-yl acetate (S1, 1.42 g, 7.50 mmol) in THF (2 mL). The reaction mixture was allowed to warm to 22 °C before being stirred for 8 h. The resulting solution was quenched by adding a saturated aqueous solution of Na₂CO₃ (50 mL) and washed with EtOAc (30 mL × 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated. The crude product was purified using silica gel column chromatography (100% hexanes), and the desired allene 1n (898 mg, 6.23 mmol, 83%) was obtained as a colorless oil. This compound has been previously reported, and our experimental

⁽⁴⁾ H. R. Yuan and J. B. Wang, Org. Chem. Front., 2022, 9, 5899-5905.

spectral data match the previously reported data.^{3a} ¹**H** NMR (CDCl₃, 400 MHz): δ 7.46 (d, *J* = 4.0 Hz, 4H), 7.37-7.33 (m, 1H), 6.20-6.19 (m, 1H), 2.01 (s, 3H), 2.00 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 203.0, 135.8, 128.3, 126.5, 126.3, 98.9, 92.5, 20.1.

(3-Methylhepta-1,2-dien-1-yl)benzene (1p). This compound has been previously reported, and the spectral data match the described data.^{3a} ¹H NMR
(CDCl₃, 400 MHz): δ 7.31-7.28 (m, 4H), 7.20-7.18 (m, 1H), 6.06 (sext, J = 2.8 Hz, 1H), 2.11-2.07 (m, 2H), 1.82 (d, J = 2.7 Hz 3H), 1.50-1.44 (m, 2H), 1.40-1.34 (m, 2H), 0.91 (t, J = 7.1 Hz, 3H); ¹³C{¹H}
NMR (CDCl₃, 100 MHz): 202.6, 136.1, 128.5, 126.5, 126.3, 103.8, 93.7, 33.8, 29.7, 22.4, 18.8, 14.0.

1-Fluoro-4-(3-methylhepta-1,2-dien-1-yl)benzene (1q). Compound **1q** was synthesized from 1-(4-fluorophenyl)hept-2-yn-1-yl acetate (2.01 g, 8.10 mmol) in 84% yield (1.39 g, 6.80 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (100% hexanes). **IR** (neat): 2962 (w), 2932 (w), 2870 (w), 2361 (m), 1736 (m), 1605 (s), 1504 (w), 1458 (m), 1373 (s), 1296 (w), 1227 (mw), 1157 (s), 1095 (s), 964 (m), 849 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.27-7.24 (m, 2H), 7.03-6.99 (m, 2H), 6.06 (sext, J = 2.8 Hz, 1H), 2.12 (td, J = 7.5, 2.7 Hz, 2H), 1.84 (d, J = 3.2 Hz, 3H), 1.52-1.46 (m, 2H), 1.43-1.37 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); ¹³C{**1H**} **NMR** (CDCl₃, 100 MHz): δ 202.4, 162.8, 160.4 (d, $J_{C-F} = 244.7$ Hz), 132.0, 127.8 (d, $J_{C-F} = 7.7$ Hz), 115.3 (d, $J_{C-F} = 22.2$ Hz), 104.0, 92.8, 33.8, 29.7, 22.4, 18.8, 13.9; ¹⁹F NMR (CDCl₃, 75.2 Hz): δ -114.40; **HRMS** (EI) *m/z*: [M]⁺ Calcd for C₁₄H₁₇F 204.1314, Found 204.1309.

Cl **1-Chloro-3-(3-methylhepta-1,2-dien-1-yl)benzene (1r)**. Compound **1r** was synthesized from 1-(3-chlorophenyl)hept-2-yn-1-yl acetate (741 mg, 2.80 mmol) in 93% yield (574 mg, 2.60 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (100% hexanes). **IR** (neat): 3055 (w), 2955 (m), 2932 (w), 2862 (m), 2361 (m), 1952 (m), 1736 (w), 1589 (s), 1474 (s), 1443 (s), 1373 (s), 1273 (s), 1196 (s), 1119 (s), 1080 (s), 879 (s), 687 (s) cm⁻¹; **¹H NMR** (CDCl₃, 400 MHz): δ 7.27-7.25 (m, 1H), 7.23-7.19 (m, 1H), 7.14-7.12 (m, 2H), 6.00 (sext, J = 2.7 Hz, 1H), 2.11-2.06 (m, 2H), 1.81 (d, J = 2.3 Hz, 3H), 1.50-1.42 (m, 2H), 1.41-1.34 (m, 2H), 0.90 (t, J = 6.9 Hz, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 203.0, 138.2, 134.4, 129.6, 126.3, 124.6, 104.4, 92.9, 33.7, 29.6, 22.4, 18.7, 13.9; **HRMS** (EI) m/z: [M]⁺ Calcd for C₁₄H₁₇Cl 220.1019, Found 220.1014.

Br 1-Bromo-3-(3-methylhepta-1,2-dien-1-yl)benzene (1s): Compound 1s was synthesized from 1-(3-bromophenyl)hept-2-yn-1-yl acetate (928 mg, 3.00 mmol) in 81% yield (644 mg, 2.43 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (100% hexanes). This compound has been previously reported, and the spectral data match the described data.^{5 1}H NMR (CDCl₃, 400 MHz): δ 7.41 (s, 1H), 7.31-7.27 (m, 1H), 7.19-7.13 (m, 2H), 5.99 (sext, J = 2.9 Hz, 1H), 2.12-2.06 (m, 2H), 1.82 (d, J = 2.7 Hz, 3H), 1.50-1.42 (m, 2H), 1.43-1.33 (m, 2H), 0.91 (t, J = 7.1 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): 203.0, 138,5, 130.0, 129.2, 129.1, 125.1, 122.7, 104.5, 92.7, 33.6, 29.5, 22.4, 18.8, 13.9.

2-(3-Methylhepta-1,2-dien-1-yl)naphthalene (1t). Compound 1t was synthesized from 1-(naphthalen-2-yl)hept-2-yn-1-yl acetate (841 mg, 3.00 mmol) in 90% yield (638 mg, 2.70 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (100% hexanes). IR (neat): 3055 (w), 2970 (m), 2932 (w), 2862 (m), 2361 (m), 2168 (m), 2160 (w), 1952 (s), 1744 (s), 1626 (s), 1597 (s), 1443 (s), 1366 (s), 1211 (s), 1119 (s), 1072 (m), 1018 (m), 949 (s), 895 (s), 864 (s), 818 (s), 741 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.80-7.75 (m, 3H), 7.63 (d, J = 1.4 Hz, 1H), 7.50-7.39 (m, 3H), 6.24 (sext, J = 2.8 Hz, 1H), 2.16-2.11 (m, 2H), 1.86 (d, J = 2.7 Hz, 3H), 1.55-1.47 (m, 2H), 1.44-1.34 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 203.3, 133.8, 133.7, 132.4, 128.0, 127.7, 127.6, 126.1, 125.3, 125.0, 124.8, 104.0, 94.1, 33.8, 29.7, 22.5, 18.9, 13.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₈H₂₁ 237.1643, Found 237.1640.

2-(3-Methylhepta-1,2-dien-1-yl)thiophene (1u). Compound 1**u** was synthesized from 1-(thiophen-2-yl)hept-2-yn-1-yl acetate (236 mg, 1.00 mmol) in 77% yield (148 mg, 0.770 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (100% hexanes). IR (neat): 3070 (w), 2955 (s), 2924 (s), 2870 (m), 2361 (m), 1651 (m), 1458 (w), 1366 (m), 1296 (m), 1227 (m), 895 (s), 694 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.13 (dd, J = 5.0, 0.9 Hz, 1H), 7.00 (dd, J = 5.3, 3.4 Hz, 1H), 6.90-6.88 (m, 1H), 6.30 (sext, J = 2.8 Hz, 1H), 2.11 (td, J = 7.3, 2.7 Hz, 2H), 1.83 (d, J = 2.7 Hz, 3H), 1.55-1.47 (m, 2H), 1.45-1.38 (m, 2H), 0.94 $(t, J = 7.1 \text{ Hz}, 3\text{H}); {}^{13}\text{C}{}^{1}\text{H} \text{NMR} (\text{CDCl}_3, 100 \text{ MHz}): \delta 202.0, 141.2, 127.3, 123.7, 123.6, 104.2, 88.1, 100 \text{ MHz})$ 33.9, 29.6, 22.4, 18.9, 13.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₂H₁₇S 193.1051, Found 193.1054.



(5-Methylnona-3,4-dien-1-yl)benzene (1w). Compound 1w was synthesized from 1-phenylnon-4-yn-3-yl acetate (698mg, 2.70 mmol) in 84% yield (487 mg, 2.27 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (100% hexanes). This compound has been previously reported, and the spectral data

⁽⁵⁾ J. Q. Kuang, X. J. Tang and S. M. Ma, Org. Chem. Front., 2015, 2, 470-475.

match the described data.⁶ ¹**H NMR** (CDCl₃, 400 MHz): δ 7.34-7.30 (m, 2H), 7.25-7.20 (m, 3H), 5.10 (qq, *J* = 6.2, 2.8 Hz, 1H), 2.76 (t, *J* = 7.8 Hz, 2H), 2.36-2.31 (m, 2H), 1.96-1.92 (m, 2H), 1.67 (d, *J* = 2.7 Hz, 3H), 1.43-1.33 (m, 4H), 0.95 (t, *J* = 7.1 Hz, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): 201.4, 142.1, 128.5, 128.2, 125.7, 99.8, 89.4, 35.6, 33.7, 31.1, 29.7, 22.3, 19.2, 14.0.



Buta-1,2-diene-1,3-diyldibenzene (1x). Compound **1x** was synthesized from 1,3-diphenylprop-2-yn-1-yl acetate (250 mg, 1.00 mmol) in 96% yield (198 mg, 0.960 mmol) as a yellow oil. The crude product was purified using silica gel

column chromatography (100% hexanes). This compound has been previously reported, and the spectral data match the described data.⁴ ¹**H NMR** (CDCl₃, 400 MHz): δ 7.56-7.54 (m, 2H), 7.44-7.37 (m, 6H), 7.33-7.27 (m, 2H), 6.56 (q, *J* = 2.7 Hz, 1H), 2.31 (d, *J* = 2.7 Hz, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): 206.8, 136.3, 134.5, 128.7, 128.4, 127.0, 126.9 126.8, 125.8, 104.5, 96.6, 16.7.

3. Cu-Catalyzed hydroalumination of allene 1a with diisobutylaluminum hydride



The formation of allylaluminum reagent 2 was deduced by analysis of ¹H NMR spectra of protonated and deuterated products. In ¹H NMR spectra, it was found that the ratio of regioisomers varied depending upon the quenching conditions (1 N HCl quenching: **2ab-H**:**2ac-H**=>98:<2, D₂O quenching: **2ab-D**:**2ac-D**=50:50).

In a glove box, **IPrCuCl** (7.32 mg, 1.50×10^{-2} mmol) was added to a vial (8 mL) charged with a magnetic stir bar. Then, the vial was sealed with a cap (phenolic open-top cap with gray PTFE/silicone) and removed from the glove box. After purging the vial with N₂ gas for 5 min, THF (1.0 mL) and diisobutylaluminum hydride (54.0 µL, 0.300 mmol) were added. The mixture was premixed for 10 min and a solution of triisopropyl((4-methylhexa-4,5-dien-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) in THF (0.5 mL) was added. The reaction mixture was stirred at 60 °C on a preheated heating block for 3 h.

⁽⁶⁾ R. J. Sharma and L. J. Williams, Org. Lett., 2013, 15, 2202–2205.

Afterward, the reaction solution was quenched by adding an aqueous solution of 1 N HCl (1 mL), followed by washing with ethyl acetate (1 mL \times 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (100% hexanes) to afford the *protonated* product **2a-H** (**2ab-H**:**2ac-H**=>98:<2, 79.5 mg, 0.294 mmol, 98%) as a colorless oil.



Triisopropyl((4-methylhex-5-en-1-yl)oxy)silane (2ab-H). **IR** (neat): 3070 (w), 2947 (s), 2870 (s), 2731 (w), 1636 (w), 1466 (m), 1389 (w), 1250 (w), 1095 (s), 1003 (m), 895 (s), 787 (m), 679 (s) cm⁻¹; ¹**H NMR** (400 MHz, CDCl₃): δ 5.70 (ddd, J = 17.4, 10.1, 7.3 Hz, 1H), 4.99-4.90 (m, 2H), 3.67 (t, J = 6.6 Hz, 2H), 2.13 (spt, J = 6.9 Hz, 1H), 1.60-1.49 (m, 2H), 1.39-1.31 (m, 2H), 1.12-1.04 (m, 21H), 1.00 (d, J = 6.9 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ 144.7, 112.5, 63.5, 37.6, 32.7, 30.7, 20.2, 18.0, 11.9; **HRMS** (ESI) m/z: [M+H]⁺ Calcd for C₁₆H₃₅OSi 271.2457, Found 271.2439.



Triisopropyl((4-methylhex-5-en-1-yl-4-*d***)oxy)silane (2a-D).** The reaction was quenched by adding D₂O and washed with EtOAc (2 x 1 mL). The organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (100% hexanes) to afford the *deuterated* product **2a-D** (**2ab-D:2ac-D**=1:1, 80.0 mg, 0.295 mmol, 98%) as a colorless oil. **IR** (neat): 3070 (w), 2947 (s), 2870 (s), 2731 (w), 1636 (w), 1466 (m), 1389 (w), 1250 (w), 1111 (s), 1003 (m), 879 (s), 787 (w), 679 (s) cm⁻¹; ¹H **NMR** (400 MHz, CDCl₃), a 1:1 mixture of regioisomers: δ 5.70 (dd, *J* = 17.2, 10.3 Hz, 0.5H), 5.22 (t, *J* = 6.4 Hz, 0.5H), 4.99-4.90 (m, 1H), 3.69-3.64 (m, 2H), 2.12-2.02 (m, 1H), 1.69-1.61 (m, 2.5H), 1.58-1.50 (m, 2H), 1.36-1.32 (m, 1H), 1.14-1.04 (m, 21H), 0.99 (s, 1.5H); ¹³C **NMR** (100 MHz, CDCl₃), a 1:1 mixture of regioisomers: δ 144.7, 135.6, 118.2, 112.4, 63.5, 63.1, 35.8, 32.6, 31.4, 31.2, 30.6, 27.7, 23.4, 20.1, 18.0, 15.6, 12.0, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₆H₃₄DOSi 272.2520, Found 275.2503.

4. General procedure for the synthesis of β , γ -unsaturated α -quaternary amides

In a glove box, **IPrCuCl** (7.32 mg, 1.50×10^{-2} mmol) was added to a vial (8 mL) charged with a magnetic stir bar. Then, the vial was sealed with a cap (phenolic open-top cap with gray PTFE/silicone) and removed from the glove box. After purging the vial with N₂ gas for 5 min, THF (1.0 mL) and diisobutylaluminum hydride (54.0 µL, 0.300 mmol) were added. The mixture was premixed for 10 min and a solution of triisopropyl((4-methylhexa-4,5-dien-1-yl)oxy)silane (**1a**, 80.6 mg, 0.300 mmol) in THF (0.5 mL) was added. The reaction mixture was stirred at 60 °C on a preheated heating block for 3 h. Phenyl isocyanate (**3a**, 28.0 µL, 0.250 mmol) was added via a syringe to the solution, which was stirred at 60 °C for an additional 2 h. Afterward, the reaction solution was quenched by adding an aqueous solution of 1 N HCl (1 mL), followed by washing with ethyl acetate (1 mL × 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product **4aa** (95.6 mg, 0.245 mmol, 98% yield) as a colorless oil.

5. Characterization data for all products



2-Methyl-N-phenyl-5-((**triisopropylsilyl**)**oxy**)**-2-vinylpentanamide** (**4aa**). **IR** (neat): 2939 (m), 2862 (m), 1666 (m), 1597 (m), 1520 (s), 1443 (s), 1381 (m), 1311 (m), 1242 (m), 1103 (s), 879 (m), 687 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.50 (d, *J* = 8.2 Hz, 2H), 7.47 (br s, 1H), 7.31 (t, *J* = 8.0 Hz, 2H), 7.10 (t, *J* = 7.3 Hz, 1H), 6.12 (dd, *J* =17.6, 10.7 Hz, 1H), 5.41 (d, *J* = 10.5 Hz, 1H), 5.39 (d, *J* = 17.9 Hz, 1H), 3.70 (t, *J* = 6.4 Hz, 2H), 1.89-1.81 (m, 2H), 1.61-1.54 (m, 2H), 1.37 (s, 3H) 1.08-1.05 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.6, 141.9, 137.9, 128.8, 124.1, 119.7, 116.4, 63.4, 49.5, 34.1, 27.9, 21.8, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₄₀NO₂Si 390.2828, Found 390.2826.



2-Methyl-*N***-(***p***-tolyl)-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ab)**. Compound **4ab** was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and

p-tolyl isocyanate (**3b**, 32.0 µL, 0.250 mmol) in 95% yield (95.9 mg, 0.238 mmol) as a light yellow solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **mp** 40-41 °C; **IR** (neat): 3317 (w), 2939 (m), 2870 (m), 1659 (s), 1605 (s), 1520 (s), 1466 (m), 1404 (m), 1319 (m), 1242 (m), 1188 (w), 1103 (s), 818 (s), 679 (s) cm⁻¹; ¹H **NMR** (CDCl₃, 400 MHz): δ 7.44 (br s, 1H), 7.37 (d, *J* = 8.7 Hz, 2H), 7.11 (d, *J* = 8.7 Hz, 2H), 6.11 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.39 (d, *J* = 11.0 Hz, 1H), 5.38 (d, *J* = 17.4 Hz, 1H), 3.70 (t, *J* = 6.4 Hz, 2H), 2.31 (s, 3H), 1.87-1.80 (m, 2H), 1.58-1.53 (m, 2H), 1.36 (s, 3H), 1.07-1.03 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.5, 141.8, 135.2, 133.7, 129.3, 119.7, 116.5, 63.4, 49.4, 34.0, 27.9, 21.8, 20.8, 18.0, 11.8; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₄₂NO₂Si 404.2985, Found 404.2986.



N-(4-Chlorophenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ac). Compound 4ac was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and 4-chlorophenyl isocyanate (3c, 38.4 mg, 0.250 mmol) in 94% yield (100 mg, 0.236 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **mp** 109-110 °C; **IR** (neat): 3317 (w), 2947 (m), 2870 (m), 1659 (s), 1597 (m), 1528 (m), 1497 (m), 1389 (m), 1304 (m), 1242 (m), 1095 (s), 995 (m), 825 (s), 679 (s) cm⁻¹; ¹**H** NMR (CDCl₃, 400 MHz): δ 7.45 (br s, 1H), 7.42 (d, *J* = 8.7 Hz, 2H), 7.23 (d, *J* = 8.7 Hz, 2H), 6.08 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.37 (dd, *J* = 17.4, 10.1 Hz, 2H), 3.68 (t, *J* = 6.4 Hz, 2H), 1.89-1.74 (m, 2H), 1.57-1.51 (m, 2H), 1.34 (s, 3H), 1.10-0.97 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.7, 141.7, 136.5, 129.1, 128.8, 120.9, 116.7, 63.4, 49.5, 34.1, 27.9, 21.8, 18.0, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₃₉ClNO₂Si 424.2439, Found 424.2438.



N-(4-Bromophenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ad). Compound 4ad was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and 4-bromophenyl isocyanate (3d, 49.2 mg, 0.250 mmol) in 95% yield (111 mg, 0.238 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 128-129 °C; IR (neat): 3294 (w), 2939 (m), 2862 (m), 1659 (s), 1589 (m), 1520 (s), 1489 (s), 1389

(m), 1311 (m), 1242 (m), 1103 (s), 918 (m), 825 (s), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.46 (br s, 1H), 7.43-7.38 (m, 4H), 6.10 (dd, J = 17.6, 10.7 Hz, 1H), 5.40 (d, J = 10.5 Hz, 1H), 5.38 (d, J = 17.4 Hz, 1H), 3.70 (t, J = 6.4 Hz, 2H), 1.91-1.76 (m, 2H), 1.59-1.51 (m, 2H), 1.36 (s, 3H), 1.12-1.00 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.7, 141.7, 137.0, 131.8, 121.2, 116.7, 116.7, 63.4, 49.6, 34.1, 27.9, 21.8, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₃₉BrNO₂Si 468.1933, Found 468.1931.



N-(4-Iodophenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ae). Compound 4ae was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and 4-iodophenyl isocyanate (3e, 61.3 mg, 0.250 mmol) in 92% yield (119 mg, 0.231 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 131-132 °C; IR (neat): 3310 (w), 2939 (m), 2870 (m), 1659 (s), 1589 (m), 1520 (s), 1489 (s), 1389 (m), 1311 (m), 1242 (m), 1103 (s), 879 (m), 818 (s), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.57 (d, J = 9.1 Hz, 2H), 7.43 (br s, 1H), 7.26 (d, J = 8.7 Hz, 2H), 6.08 (dd, J = 17.6, 10.7 Hz, 1H), 5.37 (d, J = 11.0 Hz, 1H), 5.35 (d, J = 17.8 Hz, 1H), 3.71-3.63 (m, 2H), 1.89-1.74 (m, 2H), 1.58-1.49 (m, 2H), 1.33 (s, 3H), 1.10-0.97 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.7, 141.7, 137.8, 137.7, 121.5, 116.7, 87.2, 63.4, 49.6, 34.1, 27.9, 21.8, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₃₉INO₂Si 516.1795, Found 516.1794.



N-(4-Methoxyphenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4af). Compound 4af was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and 4-methoxyphenyl isocyanate (3f, 33.0 µL, 0.250 mmol) in 95% yield (100 mg, 0.239 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). IR (neat): 3356 (w), 2970 (m), 2862 (m), 1659 (s), 1605 (w), 1512 (s), 1466 (m), 1381 (m), 1296 (m), 1242 (s), 1111 (s), 918 (m), 825 (m), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.38 (br s, 1H), 7.36 (d, *J* = 9.1 Hz, 2H), 6.81 (d, *J* = 9.1 Hz, 2H), 6.09 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.34 (d, *J* = 11.0 Hz, 1H), 5.33 (d, *J* = 17.4 Hz, 1H), 3.75 (s, 3H), 3.67 (t, *J* = 6.4 Hz, 2H), 1.86-1.75 (m, 2H), 1.58-1.50 (m,

2H), 1.33 (s, 3H), 1.08-0.98 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.4, 156.2, 141.9, 131.0, 121.5, 116.2, 113.9, 63.4, 55.3, 49.2, 34.1, 27.9, 21.8, 17.9, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₄₂NO₃Si 420.2934, Found 420.2935.



2-Methyl-*N*-(**4**-(**trifluoromethyl**)**phenyl**)-**5**-((**triisopropylsily**)**oxy**)-**2**-**vinylpentanamide** (**4a**g). Compound **4a**g was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (**1a**, 80.6 mg, 0.300 mmol) and 4-(trifluoromethyl)phenyl isocyanate (**3g**, 62.0 μL, 0.250 mmol) in 69% yield (79.0 mg, 0.173 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 41-42 °C; **IR** (neat): 3325 (w), 2947 (m), 2870 (w), 1666 (m), 1605 (m), 1528 (s), 1466 (w), 1404 (m), 1319 (s), 1250 (w), 1165 (m), 1111 (s), 679 (s) cm⁻¹; ¹H **NMR** (CDCl₃, 400 MHz): δ 7.63 (d, *J* = 8.7 Hz, 3H), 7.56 (d, *J* = 8.7 Hz, 2H), 6.12 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.44 (d, *J* = 10.6 Hz, 1H), 5.41 (d, *J* = 17.4 Hz, 1H), 3.70 (t, *J* = 6.4 Hz, 2H), 1.90-1.81 (m, 2H), 1.59-1.53 (m, 2H), 1.38 (s, 3H), 1.07-1.02 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 174.0, 141.6, 140.9, 126.2 (q, *J*_{C-F} = 3.9 Hz), 125.9 (q, *J*_{C-F} = 32.7 Hz), 121.3 (q, *J*_{C-F} = 271.6 Hz), 119.2, 117.0, 63.4, 49.8, 34.1, 27.9, 21.8, 18.0, 11.9; ¹⁹F NMR (CDCl₃, 75.2 Hz): δ -60.01; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₃₉F₃NO₂Si 458.2702, Found 458.2702.



2-Methyl-*N***-(***o***-tolyl)-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ah)**. Compound **4ah** was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and *o*-tolyl isocyanate (**3h**, 31.0 μ L, 0.250 mmol) in 78% yield (79.2 mg, 0.196 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). IR (neat): 3325 (w), 2939 (m), 2862 (m), 1682 (s), 1589 (m), 1512 (m), 1458 (s), 1381 (m), 1250 (s), 1103 (s), 918 (m), 748 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.93 (d, *J* = 7.8 Hz, 1H), 7.46 (br s, 1H), 7.21 (t, *J* = 7.8 Hz, 1H), 7.16 (d, *J* = 7.8 Hz, 1H), 7.05 (t, *J* = 7.8 Hz, 1H), 6.18 (dd, *J* = 17.8, 10.5 Hz, 1H), 5.43 (d, *J* = 17.3 Hz, 1H), 5.43 (d, *J* = 11.4 Hz, 1H), 3.72 (t, *J* = 6.4 Hz, 2H), 2.20 (s, 3H), 1.94-1.81 (m, 2H), 1.63-1.55 (m, 2H), 1.40 (s, 3H), 1.12-1.06 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.4, 142.1, 135.8, 130.2, 128.1, 126.7, 124.6, 121.9, 116.4, 63.4, 49.6, 34.0, 27.9, 21.8, 17.9, 17.6, 11.8; **HRMS**

(ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₄₂NO₂Si 404.2985, Found 404.2986.



N-(2-Bromophenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ai). Compound 4ai was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and 2-bromophenyl isocyanate (3i, 31.0 μL, 0.250 mmol) in 82% yield (96.1 mg, 0.205 mmol) as a light greenish oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3371 (w), 2947 (m), 2862 (m), 1697 (s), 1589 (m), 1512 (s), 1435 (m), 1389 (m), 1296 (m), 1103 (s), 879 (m), 748 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 8.39 (dd, J = 8.2, 1.8 Hz, 1H), 8.15 (br s, 1H), 7.50 (dd, J = 8.2, 1.4 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 6.94 (dt, J = 7.8, 1.9 Hz, 1H), 6.14 (dd, J = 17.4, 11.0 Hz, 1H), 5.45 (d, J = 10.1 Hz, 1H), 5.44 (d, J = 17.8 Hz, 1H), 3.71 (t, J = 6.4 Hz, 2H), 1.94-1.81 (m, 2H), 1.61-1.54 (m, 2H), 1.40 (s, 3H), 1.13-1.00 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.8, 141.4, 135.8, 132.1, 128.2, 124.8, 121.4, 116.8, 113.6, 63.4, 49.9, 34.2, 27.9, 21.8, 18.0, 11.9; HRMS (ESI) *m*/*z*: [M+H]⁺ Calcd for C₂₃H₃₉BrNO₂Si 468.1933, Found 468.1933.



N-(2-Methoxyphenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4aj). Compound 4aj was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and 2-methoxyphenyl isocyanate (3j, 33.0 μL, 0.250 mmol) in 62% yield (65.1 mg, 0.155 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3387 (w), 2939 (m), 2862 (m), 1674 (m), 1605 (w), 1528 (s), 1458 (s), 1381 (w), 1250 (m), 1103 (s), 926 (s), 748 (s), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 8.39 (dd, J = 8.0, 1.6 Hz, 1H), 8.25 (br s, 1H), 7.03 (td, J = 7.8, 1.8 Hz, 1H), 6.95 (t, J = 7.8, 1.4 Hz, 1H), 6.85 (dd, J = 8.2, 1.4 Hz, 1H), 6.13 (dd, J = 17.2, 11.2 Hz, 1H), 5.40-5.35 (m, 2H), 3.86 (s, 3H), 3.70 (t, J = 6.4 Hz, 2H), 1.88-1.81 (m, 2H), 1.60-1.54 (m, 2H), 1.38 (s, 3H), 1.08-1.02 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.5, 148.0, 141.7, 127.7, 123.4, 121.0, 119.3, 116.1, 109.7, 63.5, 55.7, 49.8, 34.2, 27.9, 21.7, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₄₂NO₃Si 420.2934, Found 420.2933.



2-Methyl-*N*-(*m*-tolyl)-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ak). Compound 4ak was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and *m*-tolyl isocyanate (3k, 33.0 µL, 0.250 mmol) in 95% yield (96.2 mg, 0.238 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **mp** 63-64 °C; **IR** (neat): 3325 (w), 2947 (m), 2862 (w), 2361 (m), 2168 (m), 2129 (m), 1744 (s), 1659 (m), 1589 (m), 1535 (m), 1458 (w), 1427 (m), 1366 (s), 1304 (m), 1211 (m), 1103 (m), 1003 (mw), 918 (m), 887 (m), 779 (m), 725 (m), 687 (m) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.42 (s, 1H), 7.38 (s, 1H), 7.26 (d, *J* = 9.6, 1H), 7.19 (t, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 7.3 Hz, 1H), 6.12 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.41-5.36 (m, 2H), 3.70 (t, *J* = 6.4 Hz, 2H) 2.33 (s, 3H), 1.88-1.80 (m, 2H), 1.60-1.54 (m, 2H), 1.36 (s, 3H), 1.11-1.02 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.6, 141.9, 138.9, 137.8, 128.7, 125.0, 120.3, 116.7, 116.5, 63.5, 49.6, 34.1, 28.0, 21.9, 21.4, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₄₂NO₂Si 404.2985, Found 404.2984.



2-Methyl-N-(naphthalene-1-yl)-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4al). Compound **4al** was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (**1a**, 80.6 mg, 0.300 mmol) and 1-naphthyl isocyanate (**3l**, 36.0 µL, 0.250 mmol) in 84% yield (92.3 mg, 0.210 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **mp** 68-69 °C; **IR** (neat): 3279 (w), 2939 (m), 2862 (m), 1659 (s), 1528 (s), 1466 (m), 1389 (w), 1273 (m), 1095 (s), 795 (s), 687 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 8.05 (t, *J* = 3.7 Hz, 2H), 7.88-7.86 (m, 1H), 7.72-7.67 (m, 2H), 7.53-7.46 (m, 3H), 6.31 (dd, *J* = 17.8, 10.5 Hz, 1H), 5.54 (d, *J* = 17.4 Hz, 1H), 5.54 (d, *J* = 11.0 Hz, 1H), 3.75 (t, *J* = 6.4 Hz, 2H), 2.00-1.93 (m, 2H), 1.68-1.64 (m, 2H), 1.48 (s, 3H), 1.09-1.04 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.9, 142.2, 134.0, 132.3, 128.8, 126.8, 126.2, 125.8, 125.2, 120.0, 119.8, 116.8, 63.5, 49.8, 34.1, 28.0, 22.0, 18.0, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₇H₄₂NO₂Si 440.2985, Found 440.2984.



N-(Furan-2-ylmethyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4am). Compound 4am was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and furfuryl isocyanate (3m, 27.0 μL, 0.250 mmol) in 81% yield (79.9 mg, 0.203 mmol) as a yellow oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). IR (neat): 3356 (m), 2947 (s), 2862 (s), 2361 (m), 1659 (s), 1520 (s), 1466 (m), 1381 (w), 1250 (m), 1098 (s), 1011 (m), 918 (m), 879 (m), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.34 (t, J = 0.9 Hz, 1H), 6.31 (t, J = 2.7 Hz, 1H), 6.19 (dd, J = 3.2, 0.9 Hz, 1H), 6.04 (br s, 1H), 5.99 (dd, J = 17.6, 10.7 Hz, 1H), 5.26 (d, J = 10.5 Hz, 1H), 5.24 (d, J = 17.4 Hz, 1H), 4.40 (d, J = 5.5 Hz, 2H), 3.66 (t, J = 6.4 Hz, 2H), 1.82-1.66 (m, 2H), 1.54-1.44 (m, 2H), 1.27 (s, 3H), 1.10-1.02 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 175.3, 151.4, 142.1, 141.8, 115.8, 110.3, 107.1, 63.5, 48.5, 36.7, 34.2, 27.9, 21.6, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₂H₄₀NO₃Si 394.2777, Found 394.2776.



N-Cyclohexyl-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4an). Compound 4an was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and cyclohexyl isocyanate (3n, 32.0 μ L, 0.250 mmol) in 92% yield (91.3 mg, 0.231 mmol) as a sticky oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). IR (neat): 3348 (w), 2939 (s), 2662 (s), 2361 (m), 1636 (s), 1512 (s), 1458 (s), 1381 (m), 1250 (w), 1219 (w), 1103 (s), 1011 (w), 918 (w), 802 (w) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 5.97 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.56 (d, *J* = 8.0 Hz, 1H), 5.23 (d, *J* = 9.6 Hz, 1H), 5.22 (d, *J* = 17.9 Hz, 1H), 3.76-3.68 (m, 1H), 3.66 (t, *J* = 6.4 Hz, 2H), 1.84 (d, *J* = 8.7 Hz, 2H), 1.76-1.56 (m, 5H), 1.52-1.44 (m, 2H), 1.39-1.27 (m, 3H), 1.23 (s, 3H), 1.19-1.10 (m, 2H), 1.08-1.00 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): 174.4, 142.3, 115.4, 63.6, 48.4, 34.2, 33.0, 32.9, 27.9, 25.5, 24.7, 21.7, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₄₆NO₂Si 396.3298, Found 396.3297.



N-Benzyl-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ao). Compound 4ao was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 80.6 mg, 0.300 mmol) and benzyl isocyanate (3o, 31.0 μ L, 0.250 mmol) in 80% yield (80.8 mg, 0.200 mmol) as a yellow oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat):

3333 (w), 3032 (w), 2970 (m), 1643 (s), 1528 (s), 1458 (m), 1381 (w), 1257 (m), 1003 (m), 879 (m), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.33-7.27 (m, 3H), 7.23 (t, J = 7.8 Hz, 2H), 6.03-5.96 (m, 2H), 5.23 (d, J = 10.5 Hz, 1H), 5.22 (d, J = 17.4 Hz, 1H), 4.40 (d, J = 5.9 Hz, 2H), 3.66 (t, J = 6.4 Hz, 2H), 1.81-1.70 (m, 2H), 1.58-1.47 (m, 2H), 1.29 (s, 3H), 1.09-1.03 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 175.4, 141.9, 138.5, 128.6, 127.5, 127.3, 115.8, 63.5, 48.6, 43.6, 34.2, 27.9, 21.7, 18.0, 11.9; HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₄₂NO₂Si 404.2985, Found 404.2985.



N-(2-Chloroethyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ap). Compound 4ap was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 134 mg, 0.500 mmol) and 2-chloroethyl isocyanate (3p, 22.0 μL, 0.250 mmol) in 87% yield (81.9 mg, 0.218 mmol) as a greenish oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:10). **IR** (neat): 3371 (w), 2970 (s), 2870 (s), 2361 (m), 1651 (s), 1520 (m), 1466 (m), 1381 (w), 1250 (m), 1111 (s), 1065 (m), 1003 (m), 879 (m), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 6.18 (br s, 1H), 6.00 (dd, J = 17.7, 10.8 Hz, 1H), 5.29 (d, J = 10.1 Hz, 1H), 5.27 (d, J = 17.4 Hz, 1H), 3.67 (t, J = 6.4 Hz, 2H), 3.61-3.59 (m, 2H), 3.56 (t, J = 5.5 Hz, 2H), 1.80-1.67 (m, 2H), 1.54-1.46 (m, 2H), 1.28 (s, 3H), 1.09-1.03 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 175.7, 141.7, 115.9, 63.5, 48.6, 44.0, 41.3, 34.2, 27.9, 21.7, 18.0, 11.9; HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₃₉ClNO₂Si 376.2439, Found 376.2437.



Methyl 4-(2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamido)benzoate (4aq). Compound **4aq** was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (**1a**, 67.1 mg, 0.250 mmol) and methyl 4-isocyanatobenzoate (**3q**, 88.6 mg, 0.500 mmol) in 86% yield (96.7 mg, 0.216 mmol) as a yellow oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). **IR** (neat): 3379 (w), 2970 (m), 2870 (m), 1620 (s), 1666 (m), 1597 (m), 1528 (s), 1435 (m), 1404 (m), 1284 (s), 1173 (m), 1111 (s), 679 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 8.00 (d, *J* = 8.7 Hz, 2H), 7.63 (br s, 1H), 7.58 (d, *J* = 8.7 Hz, 2H), 6.11 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.43 (d, *J* = 11.0 Hz, 1H), 5.41 (d, *J* = 17.8 Hz, 1H), 3.90 (s, 3H), 3.70 (t, *J* = 6.2 Hz, 2H), 1.93-1.76 (m, 2H), 1.59-1.52 (m, 2H), 1.37

(s, 3H), 1.11-1.01 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.9, 166.6, 142.0, 141.6, 130.8, 125.5, 118.7, 117.0, 63.4, 52.0, 49.8, 44.0, 27.9, 21.8, 18.0, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₄₂NO₄Si 448.2883, Found 448.2882.



N-(4-Cyanophenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ar). Compound 4ar was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 67.1 mg, 0.250 mmol) and 4-cyanophenyl isocyanate (3r, 72.1 mg, 0.500 mmol) in 83% yield (86.4 mg, 0.208 mmol) as a yellow oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3371 (m), 2939 (m), 2862 (s), 2361 (m), 1690 (s), 1512 (s), 1466 (m), 1311 (m), 1250 (m), 1173 (m), 1111 (m), 1003 (w), 841 (m), 679 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.65-7.58 (m, 5H), 6.10 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.44 (d, *J* = 10.5 Hz, 1H), 5.42 (d, *J* = 17.9 Hz, 1H), 3.70 (t, *J* = 6.6 Hz, 2H), 1.92-1.78 (m, 2H), 1.58-1.51 (m, 2H), 1.37 (s, 3H), 1.11-1.00 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 174.1, 141.9, 141.4, 133.2, 119.4, 118.8, 117.2, 107.0, 63.3, 49.8, 33.9, 27.9, 21.7, 18.0, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₄H₃₉N₂O₂Si 415.2781, Found 415.2780.



2-Methyl-N-(4-(2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanoyl)phenyl)-5-

((triisopropylsilyl)oxy)-2-vinylpentanamide (5ar). Compound 5ar was synthesized from triisopropyl((4-methylhexa-4,5-diene-1-yl)oxy)silane (1a, 134 mg, 0.500 mmol) and 4-cyanophenyl isocyanate (3r, 36.0 mg, 0.250 mmol) in 70% yield (121 mg, 0.176 mmol) as a yellow oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:30). IR (neat): 3394 (w), 2947 (m), 2862 (s), 1674 (s), 1512 (s), 1381 (m), 1311 (m), 1242 (m), 1180 (m), 1103 (s), 995 (m), 879 (m), 679 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.89 (d, *J* = 8.7 Hz, 2H), 7.57 (br s, 1H), 7.50 (d, *J* = 8.7 Hz, 2H), 6.16 (dd, *J* = 17.8, 11.0 Hz, 1H), 6.10 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.41 (d, *J* = 10.1 Hz, 1H), 5.39 (d, *J* = 17.4 Hz, 1H), 5.22 (d, *J* = 10.5 Hz, 1H), 5.18 (d, *J* = 16.9 Hz, 1H), 3.69 (t, *J* = 6.4 Hz, 2H), 3.60 (t, *J* = 6.4 Hz, 2H), 2.01-1.94 (m, 1H), 1.89-1.77 (m, 3H), 1.58-1.49 (m, 4H), 1.36 (s, 3H), 1.35 (s, 3H), 1.11-0.98 (m, 42H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 202.7, 173.8, 143.3, 141.6, 140.9,

132.6, 130.7, 118.2, 116.9, 114.7, 63.5, 63.4, 53.1, 49.7, 35.1, 34.0, 27.9, 27.7, 23.2, 21.8, 18.0, 18.0, 11.9, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₄₀H₇₂NO₄Si₂ 686.5000, Found 686.4998.



2-Isobutyl-*N***-phenyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ba).** Compound **4ba** was synthesized from triisopropyl((6-methyl-4-vinylideneheptyl)oxy)silane (**1b**, 93.2 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μ L, 0.250 mmol) in 72% yield (77.8 mg, 0.180 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3384 (w), 2947 (m), 2870 (s), 2361 (m), 1659 (s), 1520 (s), 1443 (m), 1311 (m), 1242 (m), 1103 (s), 918 (m), 748 (m), 687 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.49 (d, *J* = 7.8 Hz, 2H), 7.48 (br s, 1H), 7.31 (t, *J* = 7.8 Hz, 2H), 7.09 (t, *J* = 7.3 Hz, 1H), 6.12 (dd, *J* = 17.8, 11.0 Hz, 1H), 5.43 (d, *J* = 10.5 Hz, 1H), 5.40 (d, *J* = 17.4 Hz, 1H), 3.69 (td, *J* = 6.3, 3.0 Hz, 2H), 1.98-1.90 (m, 1H), 1.86-1.68 (m, 4H), 1.58-1.50 (m, 2H), 1.11-1.03 (m, 21H), 0.93 (d, *J* = 5.9 Hz, 6H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.1, 141.3, 137.8, 128.9, 124.1, 119.6, 116.7, 63.4, 52.6, 44.4, 31.8, 27.7, 24.5, 24.2, 18.0, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₆H₄₆NO₂Si 432.3298, Found 432.3297.



N-Phenyl-2-(3-((triisopropylsilyl)oxy)propyl)-2-vinylhexanamide (4ca). Compound 4ca was synthesized triisopropyl((4-vinylideneoctyl)oxy)silane (1c, 93.2 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 µL, 0.250 mmol) in 97% yield (105 mg, 0.243 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 72-73 °C; IR (neat): 3325 (w), 2947 (m), 2862 (w), 2361 (s), 2168 (m), 2129 (m), 1744 (s), 1682 (m), 1597 (m), 1528 (m), 1435 (w), 1366 (m), 1311 (s), 1211 (m), 1103 (m), 1003 (mw), 918 (m), 887 (m), 748 (m), 687 (m) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.49 (dd, *J* = 8.7, 0.9 Hz, 2H), 7.45 (s, 1H), 7.31 (d, *J* = 7.8 Hz, 2H), 7.10 (t, *J* = 7.3 Hz, 1H), 6.07 (dd, *J* = 17.8, 11.0 Hz, 1H), 5.41 (dd, *J* = 17.0, 11.0 Hz, 2H), 3.70 (t, *J* = 6.2 Hz, 2H) 1.91-1.72 (m, 4H), 1.59-1.51 (m, 2H), 1.34-1.24 (m, 4H), 1.11-1.02 (m, 21H), 0.90 (t, *J* = 7.1 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.0, 141.2, 137.9, 128.9, 124.1, 119.7, 117.0, 63.5, 52.8, 34.8, 31.1, 27.7, 26.2, 23.3, 18.0, 14.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₆H₄₆NO₂Si 432.3298, Found 432.3297.



N-Phenyl-2-(3-((triisopropylsilyl)oxy)propyl)-2-vinylpent-4-enamide (4da). Compound 4da was synthesized from triisopropyl((4-vinylidenehept-6-en-1-yl)oxy)silane (1d, 88.4 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μL, 0.250 mmol) in 83% yield (86.3 mg, 0.208 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3394 (w), 2978 (m), 2847 (s), 2361 (m), 1666 (s), 1520 (m), 1435 (m), 1311 (m), 1242 (m), 1119 (s), 995 (s), 787 (m), 679 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.51 (br s, 1H), 7.49 (d, *J* = 7.8 Hz, 2H), 7.31 (t, *J* = 7.8 Hz, 2H), 7.10 (t, *J* = 7.3 Hz, 1H), 6.09 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.78 (td, *J* = 17.2, 7.3 Hz, 1H), 5.47 (d, *J* = 11.0 Hz, 1H), 5.42 (d, *J* = 17.4 Hz, 1H), 5.15-5.09 (m, 2H), 3.70 (td, *J* = 6.3, 2.5 Hz, 2H), 2.56 (t, *J* = 7.5 Hz, 2H), 1.93-1.78 (m, 2H), 1.62-1.55 (m, 2H), 1.11-0.98 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 172.3, 140.4, 137.7, 133.7, 128.9, 124.2, 119.7, 118.3, 117.4, 63.3, 52.6, 39.5, 31.2, 27.5, 18.0, 11.8; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₄₂NO₂Si 416.2985, Found 416.2984.



2-Phenethyl-*N***-phenyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ea).** Compound **4ea** was synthesized from triisopropyl((4-phenethylhexa-4,5-dien-1-yl)oxy)silane (**1e**, 108 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μ L, 0.250 mmol) in 99% yield (119 mg, 0.248 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3402 (w), 2978 (m), 2862 (s), 1690 (s), 1605 (m), 1435 (m), 1311 (w), 1242 (w), 1119 (s), 1018 (m), 879 (m), 748 (m), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.53 (d, *J* = 7.8 Hz, 2H), 7.54 (s, 1H), 7.35 (t, *J* = 7.8 Hz, 2H), 7.29 (d, *J* = 7.3 Hz, 2H), 7.22 (d, *J* = 7.3 Hz, 3H), 7.13 (t, *J* = 7.3 Hz, 1H), 6.17 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.53 (d, *J* = 11.0 Hz, 1H), 5.48 (d, *J* = 17.4 Hz, 1H), 3.74 (t, *J* = 5.9 Hz, 2H), 2.66-2.61 (m, 2H), 2.11-2.07 (m, 2H), 2.04-1.99 (m, 1H), 1.95-1.87 (m, 1H), 1.65-1.58 (m, 2H), 1.15-1.04 (m, 21H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 172.5, 142.2, 140.7, 137.7, 128.9, 128.4, 128.3, 125.8, 124.2, 119.7, 117.5, 63.3, 52.9, 37.2, 31.2, 30.5, 27.6, 18.0, 11.9; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₃₀H₄₆NO₂Si 480.3298, Found 480.3295.



5-(Benzyloxy)-2-methyl-*N***-phenyl-2-vinylpentanamide (4fa)**. Compound **4fa** was synthesized from (((4-methylhexa-4,5-diene-1-yl)oxy)methyl)benzene (**1f**, 60.7 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μ L, 0.250 mmol) in 98% yield (78.9 mg, 0.244 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3340 (w), 2978 (w), 2862 (w), 1666 (s), 1597 (m), 1520 (s), 1443 (s), 1373 (w), 1311 (m), 1242 (w), 1095 (s), 926 (m), 748 (s), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.52 (br s, 1H), 7.50 (dd, *J* = 8.7, 0.9 Hz, 2H), 7.36-7.29 (m, 7H), 7.11 (t, *J* = 7.8 Hz, 1H), 6.13 (t, *J* = 17.6, 10.7 Hz, 1H), 5.41 (d, *J* = 10.5 Hz, 1H), 5.38 (d, *J* = 17.8 Hz, 1H), 4.52 (s, 2H), 3.51 (t, *J* = 6.4 Hz, 2H), 1.91-1.85 (m, 2H), 1.69-1.64 (m, 2H), 1.39 (s, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.5, 141.6, 138.4, 137.8, 128.9, 128.3, 127.6, 127.5, 124.1, 119.6, 116.6, 72.9, 70.4, 49.5, 34.3, 24.8, 21.8; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₆NO₂ 324.1964, Found 324.1963.



6-Chloro-2-methyl-N-phenyl-2-vinylhexanamide (4ga). Compound **4ga** was synthesized from 7-chloro-3-methylhepta-1,2-diene (**1g**, 43.4 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μ L, 0.250 mmol) in 89% yield (59.1 mg, 0.222 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3333 (w), 2978 (m), 2870 (m), 1674 (s), 1597 (s), 1528 (s), 1311 (m), 1242 (w), 1119 (m), 1011 (m), 926 (m), 748 (s), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.50 (d, *J* = 7.8 Hz, 2H), 7.47 (br s, 1H), 7.32 (t, *J* = 7.8 Hz, 2H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.13 (dd, *J* = 17.6, 10.7 Hz, 1H), 5.43 (d, *J* = 10.5 Hz, 1H), 5.39 (d, *J* = 17.8 Hz, 1H), 3.55 (t, *J* = 6.6 Hz, 2H), 1.84-1.75 (m, 4H), 1.54-1.42 (m, 2H), 1.38 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.5, 141.4, 137.7, 128.9, 124.3, 119.6, 117.0, 49.7, 44.8, 37.2, 32.9, 21.8, 21.7; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₁CINO 266.1312, Found 266.1311.



2-Methyl-2-phenethyl-*N***-phenylbut-3-enamide (4ha)**. Compound **4ha** was synthesized from (3methylpenta-3,4-dien-1-yl)benzene (**1h**, 47.5 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μ L, 0.250 mmol) in 93% yield (64.7 mg, 0.232 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 83-84 °C; IR (neat): 3325 (w), 2939 (w), 1659 (s), 1597 (s), 1535 (s), 1435 (s), 1319 (m), 1234 (m), 1180 (w), 918 (s), 748 (s), 694 (s) cm⁻¹; ¹H **NMR** (CDCl₃, 400 MHz): δ 7.55-7.53 (m, 3H), 7.37-7.28 (m, 4H), 7.24-7.19 (m, 3H), 7.13 (t, *J* = 7.3 Hz, 1H), 6.23 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.48 (dd, *J* = 11.0, 0.9 Hz, 1H), 5.45 (dd, *J* = 17.4, 0.9 Hz, 1H), 2.68-2.63 (m, 2H), 2.12-2.07 (m, 2H), 1.47 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.3, 142.1, 141.5, 137.8, 128.9, 128.4, 128.3, 125.8, 124.3, 119.7, 116.9, 49.8, 40.1, 30.8, 21.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₂NO 280.1701, Found 280.1700.



2-(2-Chlorophenethyl)-2-methyl-*N***-phenylbut-3-enamide (4ia)**. Compound **4ia** was synthesized from 1-chloro-2-(3-methylpenta-3,4-dien-1-yl)benzene (**1i**, 57.8 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μ L, 0.250 mmol) in 92% yield (72.1 mg, 0.230 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **mp** 64-65 °C; **IR** (neat): 3340 (w), 1659 (s), 1597 (s), 1535 (s), 1497 (m), 1435 (m), 1319 (m), 1250 (m), 1173 (m), 1041 (m), 918 (m), 748 (s), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.57-7.50 (m, 3H), 7.36-7.32 (m, 3H), 7.27-7.25 (m, 1H), 7.19 (td, *J* = 7.4, 1.6 Hz, 1H), 7.16-7.10 (m, 2H), 6.23 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.49 (d, *J* = 17.4 Hz, 1H), 5.45 (d, *J* = 10.1 Hz, 1H), 2.81-2.69 (m, 2H), 2.13-1.98 (m, 2H), 1.49 (s, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.2, 141.3, 139.6, 137.7, 133.7, 130.4, 129.4, 128.9, 127.4, 126.7, 124.2, 119.7, 117.0, 49.8, 38.0, 28.7, 21.6; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₁CINO 314.1312, Found 314.1313.



2-(2-Bromophenethyl)-2-methyl-*N***-phenylbut-3-enamide (4ja)**. Compound **4ja** was synthesized from 1-bromo-2-(3-methylpenta-3,4-dien-1-yl)benzene (**1j**, 71.1 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μL, 0.250 mmol) in 98% yield (87.8 mg, 0.245 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 78-79 °C; **IR** (neat): 3333 (w), 2932 (w), 1659 (s), 1597 (s), 1535 (s), 1497 (m), 1435 (m), 1319 (s), 1250 (m), 1173 (m), 1018 (m), 918 (s), 748 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.55-7.51 (m, 4H), 7.34 (t, *J* = 7.8 Hz, 2H), 7.28-7.22 (m, 2H), 7.12 (t, *J* = 7.5 Hz, 1H), 7.09-7.04 (m, 1H), 6.25 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.49 (d, *J* = 17.4 Hz, 1H), 5.46 (d, *J* = 10.1 Hz, 1H), 2.83-2.70 (m, 2H), 2.13-1.97 (m, 2H), 1.49 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.2, 141.4, 141.3, 137.7, 132.7, 130.4, 128.9, 127.7, 127.6, 124.2, 124.2,

119.7, 117.0, 49.7, 38.2, 31.3, 21.6; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₁BrNO 358.0807, Found 358.0807.



2-(4-Fluorophenylethyl)-2-methyl-*N***-phenylbut-3-enamide (4ka)**. Compound **4ka** was synthesized from 1-fluoro-4-(3-methylpenta-3,4-dien-1-yl)benzene (**1k**, 52.9 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 µL, 0.250 mmol) in 89% yield (66.5 mg, 0.224 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 77-78 °C; **IR** (neat): 3340 (m), 2986 (w), 2939 (w), 1659 (s), 1597 (s), 1535 (s), 1504 (s), 1435 (s), 1311 (m), 1219 (s), 1088 (w), 1003 (w), 918 (s), 756 (s), 694 (s) cm⁻¹; **¹H NMR** (CDCl₃, 400 MHz): δ 7.54-7.50 (m, 3H), 7.34 (t, *J* = 8.0 Hz, 2H), 7.18-7.10 (m, 3H), 6.97 (t, *J* = 8.9 Hz, 2H), 6.21 (dd *J* = 17.6, 10.7 Hz, 1H), 5.49-5.42 (m, 2H), 2.64-2.59 (m, 2H), 2.07-2.03 (m, 2H), 1.45 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.2, 161.2 (d, *J*_{C-F} = 243.7 Hz), 141.3, 137.7, 137.6 (d, *J*_{C-F} = 2.9 Hz), 129.6 (d, *J*_{C-F} = 7.7 Hz), 128.9, 124.3, 119.7, 117.1, 115.0 (d, *J*_{C-F} = 21.2 Hz), 49.8, 40.2, 30.0, 21.9; ¹⁹F NMR (CDCl₃, 75.2 Hz): δ - 68.61; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₁FNO 298.1607, Found 298.1607.



2-(3-Methoxyphenethyl)-2-methyl-*N***-phenylbut-3-enamide (4la)**. Compound **4la** was synthesized from 1-methoxy-3-(3-methylpenta-3,4-dien-1-yl)benzene (**1l**, 56.5 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μ L, 0.250 mmol) in 89% yield (68.9 mg, 0.223 mmol) as a light yellow oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). **IR** (neat): 3340 (m), 2978 (m), 2870 (m), 1666 (s), 1597 (s), 1520 (s), 1435 (s), 1311 (m), 1257 (s), 1157 (s), 1049 (m), 926 (s), 748 (s), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.54-7.52 (m, 3H), 7.34 (t, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 7.8 Hz, 1H), 7.13 (t, *J* = 7.3 Hz, 1H), 6.82 (d, *J* = 8.2 Hz, 1H), 6.75 (m, 2H), 6.22 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.48 (d, *J* = 11.0 Hz, 1H), 5.45 (d, *J* = 17.9 Hz, 1H), 3.80 (s, 3H), 2.65-2.61 (m, 2H), 2.11-2.07 (m, 2H), 1.46 (s, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.3, 159.6, 143.7, 141.4, 137.7, 129.3, 128.9, 124.3, 120.7, 119.7, 117.0, 113.9, 111.2, 55.1, 49.8, 39.9, 30.9, 21.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₀H₂₄NO₂ 310.1807, Found 310.1806.



2-(4-(*tert***-Butyl)phenyl)-2-methyl-***N***-phenylbut-3-enamide (4ma). Compound 4ma was synthesized from 1-(buta-2,3-dien-2-yl)-4-(***tert***-butyl)benzene (1m, 55.9 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 \muL, 0.250 mmol) in 59% yield (45.1 mg, 0.147 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 112-113 °C; IR (neat): 3310 (m), 3063 (w), 2962 (m), 1659 (s), 1597 (m), 1535 (s), 1443 (m), 1319 (m), 1250 (m), 1111 (m), 1018 (m), 926 (m), 833 (s), 687 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): \delta 7.46-7.40 (m, 4H), 7.34-7.28 (m, 4H), 7.17 (br s, 1H), 7.09 (t,** *J* **= 7.5 Hz, 1H), 6.39 (dd,** *J* **= 17.4, 11.0 Hz, 1H), 5.37 (d,** *J* **= 10.7 Hz, 1H), 5.21 (d,** *J* **= 17.4 Hz, 1H), 1.75 (s, 3H), 1.34 (s, 9H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): \delta 173.0, 150.3, 141.8, 139.8, 137.8, 128.9, 127.0, 125.8, 124.3, 119.7, 116.3, 55.1, 34.5, 31.3, 24.6; HRMS (ESI)** *m/z***: [M+H]⁺ Calcd for C₂₁H₂₆NO 308.2014, Found 308.2015.**



(*E*)-2,2-Dimethyl-*N*,4-diphenylbut-3-enamide (4na). Compound 4na was synthesized from (3-methylbuta-1,2-dien-1-yl)benzene (1n, 43.3 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 71% yield (46.9 mg, 0.177 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). mp 90-91 °C; IR (neat): 3286 (m), 2970 (m), 1659 (s), 1597 (s), 1520 (s), 1497 (m), 1435 (m), 1311 (m), 1242 (m), 1149 (m), 1034 (m), 972 (m), 748 (s), 687 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.52-7.47 (m, 5H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.33-7.29 (m, 3H), 7.11 (t, *J* = 7.3 Hz, 1H), 6.70 (d, *J* = 16.0 Hz, 1H), 6.49 (d, *J* = 16.0 Hz, 1H), 1.53 (s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 174.2, 137.8, 136.3, 133.9, 130.3, 128.9, 128.7, 128.0, 126.4, 124.2, 119.7, 46.0, 25.2; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₈H₂₀NO 266.1545, Found 266.1545.



(*E*)-*N*-Phenyl-1-styrylcyclohexane-1-carboxamide (40a). Compound 40a was synthesized from (2-cyclohexylidenevinyl)benzene (10, 55.3 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 76% yield (58.2 mg, 0.191 mmol) as a white solid. The crude product was purified using silica

gel column chromatography (EtOAc:hexanes = 1:40). **mp** 91-92 °C; **IR** (neat): 3286 (m), 2932 (m), 1651 (s), 1597 (m), 1528 (s), 1443 (m), 1311 (m), 1250 (m), 1165 (m), 1080 (m), 1034 (m), 972 (m), 748 (s), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.55 (br s, 1H), 7.49 (d, *J* = 6.9 Hz, 2H), 7.44 (d, *J* = 7.8 Hz, 2H), 7.36 (t, *J* = 7.1 Hz, 2H), 7.28 (t, *J* = 7.8 Hz, 3H), 7.07 (t, *J* = 7.3 Hz, 1H), 6.64 (d, *J* = 16.5 Hz, 1H), 6.28 (d, *J* = 16.5 Hz, 1H), 2.20-2.14 (m, 2H), 1.88-1.85 (m, 2H), 1.65-1.45 (m, 6H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.5, 137.9, 136.6, 133.2, 131.9, 128.9, 128.7, 127.9, 126.3, 124.1, 119.8, 50.2, 33.8, 25.6, 22.4; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₄NO 306.1858, Found 306.1859.



(*E*)-2-Methyl-*N*-phenyl-2-styrylhexanamide (4pa). Compound 4pa was synthesized from (3-methylhepta-1,2-dien-1-yl)benzene (1p, 55.9 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 77% yield (59.2 mg, 0.193 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). mp 96-97 °C; IR (neat): 3279 (m), 2962 (m), 1659 (s), 1597 (m), 1520 (s), 1435 (m), 1311 (m), 1242 (m), 1149 (m), 1134 (m), 1080 (m), 972 (m), 748 (s), 694 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.52-7.47 (m, 5H), 7.40 (t, *J* = 7.5 Hz, 2H), 7.32 (t, *J* = 7.5 Hz, 3H), 7.11 (t, *J* = 7.3 Hz, 1H), 6.68 (d, *J* = 16.4 Hz, 1H), 6.50 (d, *J* = 16.4 Hz, 1H), 1.89 (t, *J* = 7.5 Hz, 2H), 1.51 (s, 3H), 1.38-1.36 (m, 4H), 0.95 (t, *J* = 7.4 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 174.1, 138.0, 136.7, 133.2, 131.2, 129.1, 128.9, 128.1, 126.6, 124.4, 120.0, 49.6, 38.7, 26.9, 23.4, 22.7, 14.2; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₆NO 308.2014, Found 308.2015.



(*E*)-2-(4-Fluorostyryl)-2-methyl-*N*-phenylhexanamide (4qa). Compound 4qa was synthesized from 1-fluoro-4-(3-methylhepta-1,2-dien-1-yl)benzene (1q, 61.3 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 92% yield (74.9 mg, 0.230 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20). mp 117-118 °C; IR (neat): 3279 (m), 2970 (m), 1659 (s), 1597 (m), 1512 (s), 1443 (m), 1311 (m), 1227 (s), 1157 (m), 972 (m), 818 (m), 756 (s), 702 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.50 (d, *J* = 7.8 Hz, 2H), 7.45 (br s, 1H), 7.43 (dd, *J* = 8.7, 5.5 Hz, 2H), 7.31 (t, *J* = 8.0 Hz, 2H), 7.12-7.04 (m, 3H), 6.62 (d, *J* = 16.5 Hz, 1H), 6.40 (d, *J* = 16.5 Hz, 1H), 1.87 (t, *J* = 7.5 Hz, 2H), 1.49 (s, 3H), 1.39-1.34 (m, 4H), 0.94 (t, *J* = 6.9 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.8, 162.5 (d, *J*_{C-F} = 247.6 Hz), 137.8, 132.8 (d, *J*_{C-F} = 2.9 Hz),

132.7 (d, $J_{C-F} = 3.9$ Hz), 129.7, 128.9, 127.9 (d, $J_{C-F} = 7.7$ Hz), 124.2, 119.8, 115.6 (d, $J_{C-F} = 21.2$ Hz), 49.3, 38.6, 26.7, 23.2, 22.4, 14.0; ¹⁹F NMR (CDCl₃, 75.2 Hz): δ -68.54; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₅FNO 326.1920, Found 326.1920.



(*E*)-2-(3-Chlorostyryl)-2-methyl-*N*-phenylhexanamide (4ra). Compound 4ra was synthesized from 1-chloro-3-(3-methylhepta-1,2-dien-1-yl)benzene (1r, 66.2 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 81% yield (69.2 mg, 0.202 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). IR (neat): 3348 (m), 2970 (m), 1666 (s), 1597 (s), 1520 (s), 1443 (m), 1311 (m), 1242 (m), 1119 (s), 1034 (m), 972 (m), 756 (s), 694 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.47 (d, *J* = 8.2 Hz, 2H), 7.42 (s, 1H), 7.37 (br s, 1H), 7.31-7.25 (m, 5H), 7.08 (t, *J* = 7.3 Hz, 1H), 6.57 (d, *J* = 16.4 Hz, 1H), 6.47 (d, *J* = 16.4 Hz, 1H), 1.86-1.82 (m, 2H), 1.46 (s, 3H), 1.36-1.33 (m, 2H), 1.25 (t, *J* = 7.1 Hz, 2H), 0.96 (t, *J* = 6.6 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.5, 138.4, 137.7, 134.7, 129.9, 129.6, 128.9, 127.9, 126.3, 124.6, 124.3, 120.1, 119.8, 49.4, 38.6, 26.7, 23.2, 22.3, 14.0; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₅ClNO 342.1625, Found 342.1624.



(*E*)-2-(3-Bromostyryl)-2-methyl-*N*-phenylhexanamide (4sa). Compound 4sa was synthesized from 1bromo-3-(3-methylhepta-1,2-dien-1-yl)benzene (1s, 79.6 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 µL, 0.250 mmol) in 94% yield (90.8 mg, 0.235 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). **IR** (neat): 3325 (m), 2978 (m), 1666 (s), 1597 (s), 1520 (s), 1443 (m), 1312 (m), 1242 (m), 1126 (m), 1072 (m), 972 (m), 748 (s), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.61 (s, 1H), 7.50 (d, *J* = 7.8 Hz, 2H), 7.43-7.30 (m, 5H), 7.24 (t, *J* = 7.8 Hz, 1H), 7.11 (t, *J* = 7.3 Hz, 1H), 6.58 (d, *J* = 16.5 Hz, 1H), 6.49 (d, *J* = 16.5 Hz, 1H), 1.88-1.85 (m, 2H), 1.48 (s, 3H), 1.38-1.32 (m, 4H), 0.93 (t, *J* = 6.6 Hz, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.5, 138.6, 137.7, 134.7, 130.8, 130.2, 129.5, 129.2, 128.9, 125.1, 124.3, 122.9, 119.8, 49.4, 38.5, 26.7, 23.2, 22.3, 14.0; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₅BrNO 386.1120, Found 386.1122.



(*E*)-2-Methyl-2-(2-(naphthalen-2-yl)vinyl)-*N*-phenylhexanamide (4ta). Compound 4ta was synthesized from 2-(3-methylhepta-1,2-dien-1-yl)naphthalene (1t, 70.9 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 90% yield (80.4 mg, 0.225 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). **IR** (neat): 3340 (m), 2970 (m), 1666 (s), 1597 (m), 1520 (s), 1443 (m), 1311 (m), 1242 (m), 1119 (m), 972 (m), 810 (m), 748 (s), 694 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.88-7.84 (m, 4H), 7.69 (d, *J* = 8.7 Hz, 1H), 7.55-7.48 (m, 5H), 7.32 (t, *J* = 7.3 Hz, 2H), 7.11 (t, *J* = 7.6 Hz, 1H), 6.85 (d, *J* = 16.5 Hz, 1H), 6.63 (d, *J* = 16.5 Hz, 1H), 1.95-1.91 (m, 2H), 1.56 (s, 3H), 1.42-1.39 (m, 4H), 0.98-0.95 (m, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 174.0, 137.8, 133.8, 133.5, 133.2, 133.0, 131.1, 128.9, 128.4, 127.9, 127.7, 126.5, 126.5, 126.1, 124.2, 123.2, 119.7, 49.5, 38.6, 26.7, 23.3, 22.5, 14.0; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₂₈NO 358.2171, Found 358.2170.



(*E*)-2-Methyl-*N*-phenyl-2-(2-(thiophen-2-yl)vinyl)hexanamide (4ua). Compound 4ua was synthesized from 2-(3-methylhepta-1,2-dien-1-yl)thiophene (1u, 57.7 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 82% yield (64.3 mg, 0.205 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:30). mp 115-116 °C; **IR** (neat): 3294 (m), 2970 (m), 1659 (s), 1597 (m), 1520 (s), 1445 (m), 1311 (m), 1242 (m), 1126 (m), 964 (m), 810 (m), 748 (s), 702 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.50 (d, *J* = 7.8 Hz, 2H), 7.43 (br s, 1H), 7.31 (t, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 5.0 Hz, 1H), 7.10 (t, *J* = 7.8 Hz, 1H), 7.04-7.01 (m, 2H), 6.78 (d, *J* = 16.5 Hz, 1H), 6.30 (d, *J* = 16.4 Hz, 1H), 1.86-1.82 (m, 2H), 1.46 (s, 3H), 1.39-1.31 (m, 4H), 0.93 (t, *J* = 6.9 Hz, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.7, 141.7, 137.8, 132.4, 128.9, 127.6, 126.1, 124.6, 124.5, 124.3, 119.8, 49.4, 38.6, 26.7, 23.2, 22.5, 14.0; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₄NOS 314.1579, Found 314.1580.



(E)-2-Methyl-N,2,4-triphenylbut-3-enamide (4xa-1). Compound 4xa-1 was synthesized from buta-

1,2-diene-1,3-diyldibenzene (**1x**, 61.9 mg, 0.300 mmol) and phenyl isocyanate (**3a**, 27.0 μL, 0.250 mmol) in 39% yield (31.9 mg, 0.0974 mmol) as a white foaming. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). **IR** (neat): 3032 (m), 2986 (m), 1728 (s), 1674 (s), 1520 (s), 1443 (m), 1311 (m), 1211 (m), 1072 (m), 972 (m), 910 (m), 748 (s), 694 (s) cm⁻¹; ¹H **NMR** (CDCl₃, 400 MHz): δ 7.48-7.41 (m, 8H), 7.37-7.29 (m, 6H), 7.21 (br s, 1H), 7.11 (t, J = 7.5 Hz, 1H), 6.78 (d, J = 16.5 Hz, 1H), 6.48 (d, J = 16.1 Hz, 1H), 1.87 (s, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 172.9, 143.3, 137.7, 136.6, 133.4, 129.7, 129.3, 128.9, 128.6, 127.9, 127.5, 127.5, 126.5, 124.4, 119.7, 55.1, 25.4; **HRMS** (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₂NO 328.1701, Found 328.1701.



(*E*)-*N*,2,4-triphenylpent-3-enamide (4xa-2). Compound 4xa-2 was synthesized from buta-1,2-diene-1,3-diyldibenzene (1x, 61.9 mg, 0.300 mmol) and phenyl isocyanate (3a, 27.0 µL, 0.250 mmol) in 35% yield (28.6 mg, 0.0873 mmol) as a white solid. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:40). **mp** 130-131 °C; **IR** (neat): 3294 (m), 3063 (m), 1659 (s), 1597 (s), 1543 (s), 1497 (m), 1375 (m), 1250 (m), 1080 (m), 1026 (m), 887 (m), 756 (s), 694 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.50-7.37 (m, 9H), 7.35-7.28 (m, 6H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.33 (dd, *J* = 9.1, 1.4 Hz, 1H), 4.72 (d, *J* = 8.7 Hz, 1H), 2.16 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 170.4, 142.7, 139.5, 139.2, 137.7, 129.1, 128.9, 128.3, 128.1, 127.5, 127.4, 125.9, 125.3, 124.4, 119.8, 53.8, 16.6; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₃H₂₂NO 328.1701, Found 328.1702.



N-Phenyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ya). Compound 4ya was synthesized from (hexa-4,5-dien-1-yloxy)triisopropylsilane (1y, 127.2 mg, 0.500 mmol) and phenyl isocyanate (3a, 27.0 μ L, 0.250 mmol) in 90% yield (84.5 mg, 0.225 mmol) as a colorless oil. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:30). **IR** (neat): 3302 (m), 2939 (m), 2862 (m), 1659 (s), 1605 (m), 1543 (s), 1443 (m), 1103 (s), 995 (m), 879 (m), 748 (s), 687 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.51 (d, *J* = 7.8 Hz, 2H), 7.32 (t, *J* = 7.8 Hz, 2H), 7.32 (br s, 1H), 7.11 (d, *J* = 7.3 Hz, 1H), 5.99-5.90 (m, 1H), 5.31-5.27 (2H), 3.79-3.69 (m, 2H), 3.04 (q, *J* = 7.4 Hz, 1H), 2.06-1.99 (m, 1H), 1.75-1.58 (m, 3H), 1.15-1.03 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 171.3, 137.8, 137.1, 129.0, 124.2, 119.7, 118.4, 63.2, 52.6, 30.4, 28.2, 18.0, 12.0; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for

C₂₂H₃₈NO₂Si 376.2672, Found 376.2653.

6. Procedure for gram-scale reaction

In a glove box, IPrCuCl (97.5 mg, 0.200 mmol) was added to a round bottomed flask (100 mL) charged with a magnetic stir bar, and the flask was sealed with a rubber septum equipped with a reflux condenser and removed from the glove box. After purging the flask with N₂ gas for 5 min, THF (13.3 mL) and diisobutylaluminum hydride (0.713 mL, 4.00 mmol) were added. The reaction mixture was premixed for 10 min and a solution of triisopropyl((4-methylhexa-4,5-dien-1-yl)oxy)silane (**1a**, 1.07 g, 4.00 mmol) in THF (6.7 mL) was added. The reaction solution was stirred at 60 °C on a preheated heating block for 3 h. Then, phenyl isocyanate (**3a**, 0.362 mL, 3.33 mmol) was added slowly via a syringe to the solution, which was stirred at 60 °C for an additional 2 h. The resulting solution was quenched by adding an aqueous solution of 1 N HCl (13 mL), followed by washing with ethyl acetate (EtOAc) (15 mL× 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20) to produce the desired product **4aa** (1.43 g, 3.67 mmol, 92% yield) as a colorless oil.

7. Synthetic applications

(1) Synthesis of a six-membered lactam 7





and concentrated in vacuo. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20) to obtain the allylated product **6** (184 mg, 0.428 mmol, 86%) as a sticky colorless oil. **IR** (neat): 3055 (w), 2947 (m), 2862 (m), 2361 (s), 2168 (m), 1736 (s), 1597 (m), 1528 (m), 1443 (m), 1373 (s), 1311 (s), 1211 (s), 1111 (s), 1003 (w), 926 (m), 887 (m), 748 (m), 687 (m) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.28 (t, *J* = 6.9 Hz, 3H), 7.13-7.10 (m, 2H), 5.93-5.83 (m, 1H), 5.67 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.08 (d, *J* = 10.1 Hz, 1H), 5.01 (dd, *J* = 17.4, 1.4 Hz, 1H), 4.65-4.59 (m, 2H), 4.21 (qd, *J* = 14.5, 6.4 Hz, 2H), 3.65 (t, *J* = 5.7 Hz, 2H), 1.72-1.54 (m, 2H), 1.53-1.47 (m, 2H), 1.16 (s, 3H), 1.11-1.03 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 174.4, 142.8, 142.5, 133.2, 128.4, 127.8, 117.7, 111.3, 63.7, 55.4, 49.4, 35.8, 28.2, 24.0, 18.0, 11.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for C₂₆H₄₄NO₂Si 430.3141, Found 430.3140.

3-Methyl-1-phenyl-3-(3-((triisopropylsilyl)oxy) propyl)-3,6-dihydropyridin-2(1H)-one (7). In the glove box, the second-generation Grubbs catalyst G-II (8.50 mg. 1.00×10^{-2} mmol) was weighed out into a vial (8 mL) charged with a magnetic bar, and the vial was sealed with a cap (phenolic open-top cap with gray PTFE/silicone) and removed from the glove box. Under N₂ gas flow, a solution of *N*-allyl-2methyl-N-phenyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (6, 86.0 mg, 0.200 mmol) in toluene (12.3 mL) was added to the vial. The reaction mixture was stirred at room temperature for 2 h. Afterward, the resulting solution was filtered through a plug of celite with Et₂O (1.5 mL \times 3). After removing all volatiles, the resulting crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:3) to produce the desired product 7 (73.7 mg, 0.183 mmol, 92%) as a pale-green oil. **IR** (neat): 2947 (w), 2862 (m), 2361 (m), 2168 (m), 2129 (m), 1744 (s), 1659 (s), 1597 (m), 1528 (w), 1466 (s), 1427 (s), 1366 (s), 1288 (s), 1211 (s), 1111(s), 995 (w), 918 (m), 887 (m), 687 (m) cm⁻¹; ¹H **NMR** (CDCl₃, 400 MHz): δ 7.43-7.39 (m, 2H), 7.30-7.26 (m, 3H), 5.83 (dt, *J* = 10.1, 3.2 Hz, 1H), 5.63 (dt, J = 10.1, 2.1 Hz, 1H), 4.24 (t, J = 2.5 Hz, 2H), 3.76-3.70 (m, 1H), 3.66-3.60 (m, 1H), 2.03-1.97 (m,1H), 1.70-1.56 (m, 2H), 1.55-1.44 (m, 1H), 1.37 (s, 3H), 1.11-1.04 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.2, 142.7, 132.8, 129.1, 126.9, 126.5, 119.6, 63.4, 52.3, 43.0, 37.5, 29.0, 27.1, 18.0, 11.9; **HRMS** (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₄H₃₉NNaO₂Si 424.2648, Found 424.2648.

(2) Synthesis of a six-membered lactam 9



5-Hydroxy-2-methyl-N-phenyl-2-vinylpentanamide (8). 2-Methyl-N-phenyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4aa, 117 mg, 0.300 mmol), THF (1.2 mL) and tetrabutvlammonium fluoride (1.0 M in THF, 0.900 mL, 0.900 mmol) were added to a vial (8 mL) under N₂ gas flow. The reaction mixture was stirred at room temperature for 1 h and quenched with a saturated aqueous solution of NH₄Cl (1 mL). After washing the solution with Et_2O (2 mL \times 3), the organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:1) to produce the alcohol product 8 (65.8) mg, 0.282 mmol, 94%) as a colorless oil. IR (neat): 3371 (w), 3063 (m), 2947 (w), 2870 (w), 2361 (m), 1859 (s), 1705 (s), 1674 (s), 1597 (s), 1528 (s), 1435 (s), 1366 (s), 1311 (s), 1227 (s), 1173 (s), 1126 (s), 1057 (s), 926 (s), 756 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.51-7.49 (m, 3H), 7.32 (t, J = 8.0 Hz, 2H), 7.11 (t, J = 7.8 Hz, 1H), 6.14 (dd, J = 17.4, 11.0 Hz, 1H), 5.43-5.38 (m, 2H), 3.67 (t, J = 6.4 Hz, 2H), 1.93-1.79 (m, 2H), 1.64-1.59 (m, 3H), 1.39 (s, 3H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 173.8, 141.3, 137.7, 128.8, 124.3, 119.7, 116.7, 62.6, 49.4, 33.9, 27.5, 22.0; **HRMS** (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₄H₁₉NNaO₂ 256.1313, Found 256.1314.

3-Methyl-1-phenyl-3-vinylpiperidin-2-one (9). Triphenylphosphine (142 mg, 0.540 mmol), di-*tert*butyl azodicarboxylate (124 mg, 0.540 mmol), and THF (2 mL) were added to a vial (8 ml) under N₂ gas flow. The solution was allowed to premix for 10 min and a solution of 5-hydroxy-2-methyl-*N*-phenyl-2vinylpentanamide (**8**, 84.5 mg, 0.360 mmol) in THF (1 mL) was added using a cannula. Then, the reaction mixture was stirred for 5 h at 60 °C on a heating block. Afterward, the resulting solution was concentrated and the remaining crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20) to obtain the lactam product **9** (70.5 mg, 0.330 mmol, 91%) as a colorless oil. **IR** (neat): 2970 (w), 2870 (m), 2361 (m), 2168 (m), 2129 (m), 1736 (s), 1651 (s), 1420 (s), 1121 (s), 1119 (s), 918 (m), 764 (m), 625 (m) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.38 (t, *J* = 7.3 Hz, 2H), 7.25-7.23 (m, 3H), 6.02 (ddd, *J* = 17.6, 10.7, 1.8 Hz, 1H), 5.21 (d, *J* = 17.4 Hz, 1H), 5.18 (d, *J* = 10.1 Hz, 1H), 3.72-3.61 (m, 2H), 2.09-2.01 (m, 2H), 1.95-1.88 (m, 2H), 1.40 (s, 3H); ¹³C{¹H} **NMR** (CDCl₃, 100 MHz): δ 173.4, 143.7, 143.6, 129.0, 126.5, 126.3 113.6, 52.0, 45.8, 34.0, 26.4, 19.9; **HRMS** (ESI) *m/z*: [M+H]⁺ Calcd for

C₁₄H₁₈NO 216.1388, Found 216.1388.

(3) Synthesis of a six-membered lactam 10



3-Methyl-4-methylene-3-(3-((triisopropylsilyl)oxy)propyl)-3,4-dihydroquinolin-2(1H)-one (10). In a glove box, Pd₂dba₃ (2.29 mg, 2.50×10^{-3} mmol) and P(*o*-tol)₃ (3.04 mg, 1.00×10^{-2} mmol) were added to a vial (4 mL) charged with a magnetic stir bar, and the vial was sealed with a cap (phenolic open-top cap with gray PTFE/silicone) and removed from the glove box. After purging the vial with N₂ gas for 5 min, a solution of N-(2-bromophenyl)-2-methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (4ai, 46.9 mg, 0.100 mmol) in DMF (0.56 mL) was added to the mixture, which was premixed for 10 min. Then, triethylamine (40.0 µL, 0.283 mmol) was added to the mixture. The reaction mixture was stirred for 12 h at 160 °C on a heating block and allowed to cool to room temperature. The resulting solution was quenched with water (2 mL) and washed with ethyl acetate (15 mL \times 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:10) to produce the desired product **10** (34.2 mg, 0.0882 mmol, 88% yield) as a colorless oil. **IR** (neat): 3209 (w), 2970 (m), 1682 (s), 1620 (m), 1481 (s), 1458 (m), 1381 (m), 1257 (m), 1088 (s), 802 (s), 748 (s) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 8.79 (br s, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.22 (td, J = 7.5, 1.4 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 5.55 (s, 1H), 5.25 (s, 1H), 3.56 (t, J = 6.2 Hz, 2H), 1.72-1.67 (m, 2H), 1.54-1.48 (m, 2H), 1.46 (s, 3H), 1.03-0.93 (m, 21H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 175.2, 145.2, 134.9, 129.1, 125.4, 123.3, 123.2, 115.0, 112.0, 63.1, 47.6, 34.6, 27.5, 19.7, 17.9, 11.9; HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₃H₃₇NNaO₂Si 410.2491, Found 410.2491.

(4) Synthesis of a seven-membered lactam 11



3-Methyl-1-phenyl-3-vinylazepan-2-one (**11**). Tetrabutylammonium bromide (3.20 mg, 1.00×10^{-2} mmol) and KOH (16.8 mg, 0.300 mmol) were added to a vial (4 mL) charged with 6-chloro-2-methyl-N-phenyl-2-vinylhexanamide (**4ga**, 26.6 mg, 0.100 mmol) and a magnetic stir bar under N₂ gas flow. CH₂Cl₂ (0.1 mL) and water (50.0 µL) were added to the vial, which was stirred for 18 h at 50 °C on a heating block. Afterward, the reaction solution was quenched by adding a saturated aqueous solution of NH₄Cl (0.1 mL) and washed with CH₂Cl₂ (0.5 mL × 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:20) to produce the desired product **11** (20.3 mg, 0.0885 mmol, 89% yield) as a light-yellow oil. **IR** (neat): 3078 (w), 2924 (m), 1651 (s), 1589 (m), 1489 (s), 1366 (m), 1335 (m), 1265 (s), 1119 (w), 910 (m), 694 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 7.37 (t, *J* = 7.8 Hz, 2H), 7.23 (t, *J* = 7.3 Hz, 1 H), 7.18 (d, *J* = 7.4 Hz, 2H), 6.08 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.23 (d, *J* = 10.0 Hz, 1H), 5.22 (d, *J* = 17.4 Hz, 1H), 4.09 (ddd, *J* = 15.2, 11.1, 1.6 Hz, 1H), 3.42 (ddd, *J* = 15.2, 5.6, 2.5 Hz, 1H), 1.90-1.78 (m, 5H), 1.74-1.69 (m, 1H), 1.34 (s, 3H); ¹³C **NMR** (CDCl₃, 100 MHz): δ 176.4, 146.6, 142.0, 129.1, 126.6, 126.4, 113.7, 51.4, 49.7, 36.6, 30.4, 28.7, 25.3; **HRMS** (ESI) m/z: [M+H]⁺ Calcd for C₁₅H₂₀NO 230.1545, Found 230.1546.

(5) Synthesis of oxazoline 12



2-(3-Methyl-6-((triisopropylsilyl)oxy)hex-1-en-3-yl)-4,5-dihydrooxazole (12).

Diazabicyclo[5.4.0]undec-7-ene (30.0 μ L, 0.200 mmol) was added to a solution of N-(2-chloroethyl)-2methyl-5-((triisopropylsilyl)oxy)-2-vinylpentanamide (**4ap**, 37.6 mg, 0.100 mmol) in CH₂Cl₂ (1.0 mL) under N₂ gas flow. The reaction mixture was stirred for 18 h at 60 °C on a heating block. The resulting solution was quenched by adding a saturated aqueous solution of NH₄Cl (1.0 mL) and washed with CH₂Cl₂ (1.0 mL × 3). The organic layers were combined, dried over MgSO₄, filtered, and concentrated in vacuo. The crude product was purified using silica gel column chromatography (EtOAc:hexanes = 1:3) to produce the desired product **12** (27.3 mg, 0.0804 mmol, 80% yield) as a colorless oil. **IR** (neat): 3010 (m), 2947 (m), 1736 (s), 1659 (s), 1466 (m), 1381 (m), 1257 (m), 1103 (s), 957 (m), 679 (s) cm⁻¹; ¹**H NMR** (CDCl₃, 400 MHz): δ 6.03 (dd, *J* = 17.4, 10.5 Hz, 1H), 5.13-5.09 (m, 2H), 4.23 (t, *J* = 9.6 Hz, 2H), 3.83 (t, *J* = 9.1 Hz, 2H), 3.66 (t, *J* = 6.5 Hz, 2H), 1.80-1.72 (m, 1H), 1.69-1.61 (m, 1H), 1.54-1.46 (m, 2H), 1.32 (s, 3H), 1.12-1.01 (m, 21H); ¹³C NMR (CDCl₃, 100 MHz): δ 172.1, 142.2, 113.2, 67.4, 63.6, 54.2, 42.5, 35.1, 28.1, 21.6, 18.0, 11.9; **HRMS** (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₃₈NO₂Si 340.2672, Found 340.2674.



8. Copies of ¹H and ¹³C NMR spectra for all products

Figure S1. ¹H NMR spectrum of the compound 1i in CDCl₃, 400 MHz



Figure S2. ¹³C NMR spectrum of the compound 1i in CDCl₃, 100 MHz



Figure S3. ¹H NMR spectrum of the compound 1j in CDCl₃, 400 MHz



Figure S4. ¹³C NMR spectrum of the compound 1j in CDCl₃, 100 MHz



Figure S5. ¹H NMR spectrum of the compound 10 in CDCl₃, 400 MHz



Figure S6. ¹³C NMR spectrum of the compound 10 in CDCl₃, 100 MHz


Figure S7. ¹H NMR spectrum of the compound 1n in CDCl₃, 400 MHz



Figure S8. ¹³C NMR spectrum of the compound 1n in CDCl₃, 100 MHz



Figure S9. ¹H NMR spectrum of the compound 1p in CDCl₃, 400 MHz



Figure S10. ¹³C NMR spectrum of the compound 1p in CDCl₃, 100 MHz



Figure S11. ¹H NMR spectrum of the compound 1q in CDCl₃, 400 MHz



Figure S12. ¹³C NMR spectrum of the compound 1q in CDCl₃, 100 MHz



Figure S13. ¹⁹F NMR spectrum of the compound 1q in CDCl₃, 75.2 MHz



Figure S14. ¹H NMR spectrum of the compound 1r in CDCl₃, 400 MHz



Figure S15. ¹³C NMR spectrum of the compound 1r in CDCl₃, 100 MHz



Figure S16. ¹H NMR spectrum of the compound 1s in CDCl₃, 400 MHz



Figure S17. ¹³C NMR spectrum of the compound 1s in CDCl₃, 100 MHz



Figure S18. ¹H NMR spectrum of the compound 1t in CDCl₃, 400 MHz



Figure S19. ¹³C NMR spectrum of the compound 1t in CDCl₃, 100 MHz



Figure S20. ¹H NMR spectrum of the compound 1u in CDCl₃, 400 MHz



Figure S21. ¹³C NMR spectrum of the compound 1u in CDCl₃, 100 MHz



Figure S22. ¹H NMR spectrum of the compound 1x in CDCl₃, 400 MHz



Figure S23. ¹³C NMR spectrum of the compound 1x in CDCl₃, 100 MHz



Figure S24. ¹H NMR spectrum of the compound 1w in CDCl₃, 400 MHz



Figure S25. ¹³C NMR spectrum of the compound 1w in CDCl₃, 100 MHz



Figure S26. ¹H NMR spectrum of the compound 2ab-H in CDCl₃, 400 MHz



Figure S27. ¹³C NMR spectrum of the compound 2ab-H in CDCl₃, 100 MHz



Figure S28. ¹H NMR spectrum of the compound 2ab-H in CDCl₃, 400 MHz



Figure S29. ¹³C NMR spectrum of the compound 2ab-H in CDCl₃, 100 MHz



Figure S30. ¹H NMR spectrum of the compound 4aa in CDCl₃, 400 MHz



Figure S31. ¹³C NMR spectrum of the compound 4aa in CDCl₃, 100 MHz



Figure S32. ¹H NMR spectrum of the compound 4ab in CDCl₃, 400 MHz



Figure S33. ¹³C NMR spectrum of the compound 4ab in CDCl₃, 100 MHz



Figure S34. ¹H NMR spectrum of the compound 4ac in CDCl₃, 400 MHz



Figure S35. ¹³C NMR spectrum of the compound 4ac in CDCl₃, 100 MHz



Figure S36. ¹H NMR spectrum of the compound 4ad in CDCl₃, 400 MHz



Figure S37. ¹³C NMR spectrum of the compound 4ad in CDCl₃, 100 MHz



Figure S38. ¹H NMR spectrum of the compound 4ae in CDCl₃, 400 MHz



Figure S39. ¹³C NMR spectrum of the compound 4ae in CDCl₃, 100 MHz



Figure S40. ¹H NMR spectrum of the compound 4af in CDCl₃, 400 MHz



Figure S41. ¹³C NMR spectrum of the compound 4af in CDCl₃, 100 MHz



Figure S42. ¹H NMR spectrum of the compound 4ag in CDCl₃, 400 MHz



Figure S43. ¹³C NMR spectrum of the compound 4ag in CDCl₃, 100 MHz



Figure S44. ¹⁹F NMR spectrum of the compound 4ag in CDCl₃, 75.2 MHz



Figure S45. ¹H NMR spectrum of the compound 4ah in CDCl₃, 400 MHz



Figure S46. ¹³C NMR spectrum of the compound 4ah in CDCl₃, 100 MHz



Figure S47. ¹H NMR spectrum of the compound 4ai in CDCl₃, 400 MHz



Figure S48. ¹³C NMR spectrum of the compound 4ai in CDCl₃, 100 MHz



Figure S49. ¹H NMR spectrum of the compound 4aj in CDCl₃, 400 MHz



Figure S50. ¹³C NMR spectrum of the compound 4aj in CDCl₃, 100 MHz



Figure S51. ¹H NMR spectrum of the compound 4ak in CDCl₃, 400 MHz



Figure S52. ¹³C NMR spectrum of the compound 4ak in CDCl₃, 100 MHz



Figure S53. ¹H NMR spectrum of the compound 4al in CDCl₃, 400 MHz



Figure S54. ¹³C NMR spectrum of the compound 4al in CDCl₃, 100 MHz



Figure S55. ¹H NMR spectrum of the compound 4am in CDCl₃, 400 MHz



Figure S56. ¹³C NMR spectrum of the compound 4am in CDCl₃, 100 MHz



Figure S57. ¹H NMR spectrum of the compound 4an in CDCl₃, 400 MHz



Figure S58. ¹³C NMR spectrum of the compound 4an in CDCl₃, 100 MHz



Figure S59. ¹H NMR spectrum of the compound 4ao in CDCl₃, 400 MHz



Figure S60. ¹³C NMR spectrum of the compound 4ao in CDCl₃, 100 MHz



Figure S61. ¹H NMR spectrum of the compound 4ap in CDCl₃, 400 MHz



Figure S62. ¹³C NMR spectrum of the compound 4ap in CDCl₃, 100 MHz



Figure S63. ¹H NMR spectrum of the compound 4aq in CDCl₃, 400 MHz



Figure S64. ¹³C NMR spectrum of the compound 4aq in CDCl₃, 100 MHz



Figure S65. ¹H NMR spectrum of the compound 4ar in CDCl₃, 400 MHz



Figure S66. ¹³C NMR spectrum of the compound 4ar in CDCl₃, 100 MHz



Figure S67. ¹H NMR spectrum of the compound 5ar in CDCl₃, 400 MHz



Figure S68. ¹³C NMR spectrum of the compound 5ar in CDCl₃, 100 MHz



Figure S69. ¹H NMR spectrum of the compound 4ba in CDCl₃, 400 MHz



Figure S70. ¹³C NMR spectrum of the compound 4ba in CDCl₃, 100 MHz



Figure S71. ¹H NMR spectrum of the compound 4ca in CDCl₃, 400 MHz



Figure S72. ¹³C NMR spectrum of the compound 4ca in CDCl₃, 100 MHz



Figure S73. ¹H NMR spectrum of the compound 4da in CDCl₃, 400 MHz



Figure S74. ¹³C NMR spectrum of the compound 4da in CDCl₃, 100 MHz



Figure S75. ¹H NMR spectrum of the compound 4ea in CDCl₃, 400 MHz



Figure S76. ¹³C NMR spectrum of the compound 4ea in CDCl₃, 100 MHz



Figure S77. ¹H NMR spectrum of the compound 4fa in CDCl₃, 400 MHz



Figure S78. ¹³C NMR spectrum of the compound 4fa in CDCl₃, 100 MHz


Figure S79. ¹H NMR spectrum of the compound 4ga in CDCl₃, 400 MHz



Figure S80. ¹³C NMR spectrum of the compound 4ga in CDCl₃, 100 MHz



Figure S81. ¹H NMR spectrum of the compound 4ha in CDCl₃, 400 MHz



Figure S82. ¹³C NMR spectrum of the compound 4ha in CDCl₃, 100 MHz



Figure S83. ¹H NMR spectrum of the compound 4ia in CDCl₃, 400 MHz



Figure S84. ¹³C NMR spectrum of the compound 4ia in CDCl₃, 100 MHz



Figure S85. ¹H NMR spectrum of the compound 4ja in CDCl₃, 400 MHz



Figure S86. ¹³C NMR spectrum of the compound 4ja in CDCl₃, 100 MHz



Figure S87. ¹H NMR spectrum of the compound 4ka in CDCl₃, 400 MHz



Figure S88. ¹³C NMR spectrum of the compound 4ka in CDCl₃, 100 MHz



Figure S89. ¹⁹F NMR spectrum of the compound 4ka in CDCl₃, 75.2 MHz



Figure S90. ¹H NMR spectrum of the compound 4la in CDCl₃, 400 MHz



Figure S91. ¹³C NMR spectrum of the compound 4la in CDCl₃, 100 MHz



Figure S92. ¹H NMR spectrum of the compound 4ma in CDCl₃, 400 MHz



Figure S93. ¹³C NMR spectrum of the compound 4ma in CDCl₃, 100 MHz



Figure S94. ¹H NMR spectrum of the compound 4na in CDCl₃, 400 MHz



Figure S95. ¹³C NMR spectrum of the compound 4na in CDCl₃, 100 MHz



Figure S96. ¹H NMR spectrum of the compound 40a in CDCl₃, 400 MHz



Figure S97. ¹³C NMR spectrum of the compound 40a in CDCl₃, 100 MHz



Figure S98. ¹H NMR spectrum of the compound 4pa in CDCl₃, 400 MHz



Figure S99. ¹³C NMR spectrum of the compound 4pa in CDCl₃, 100 MHz



Figure S100. ¹H NMR spectrum of the compound 4qa in CDCl₃, 400 MHz



Figure S101. ¹³C NMR spectrum of the compound 4qa in CDCl₃, 100 MHz



Figure S102. ¹⁹F NMR spectrum of the compound 4qa in CDCl₃, 75.2 MHz



Figure S103. ¹H NMR spectrum of the compound 4ra in CDCl₃, 400 MHz



Figure S104. ¹³C NMR spectrum of the compound 4ra in CDCl₃, 100 MHz



Figure S105. ¹H NMR spectrum of the compound 4sa in CDCl₃, 400 MHz



Figure S106. ¹³C NMR spectrum of the compound 4sa in CDCl₃, 100 MHz



Figure S107. ¹H NMR spectrum of the compound 4ta in CDCl₃, 400 MHz



Figure S108. ¹³C NMR spectrum of the compound 4ta in CDCl₃, 100 MHz



Figure S109. ¹H NMR spectrum of the compound 4ua in CDCl₃, 400 MHz



Figure S110. ¹³C NMR spectrum of the compound 4ua in CDCl₃, 100 MHz



Figure S111. ¹H NMR spectrum of the compound 4xa-1 in CDCl₃, 400 MHz



Figure S112. ¹³C NMR spectrum of the compound 4xa-1 in CDCl₃, 100 MHz



Figure S113. ¹H NMR spectrum of the compound 4xa-2 in CDCl₃, 400 MHz



Figure S114. ¹³C NMR spectrum of the compound 4xa-2 in CDCl₃, 100 MHz



Figure S115. ¹H NMR spectrum of the compound 4ya in CDCl₃, 400 MHz



Figure S116. ¹³C NMR spectrum of the compound 4ya in CDCl₃, 100 MHz



Figure 117. ¹H NMR spectrum of the compound 6 in CDCl₃, 400 MHz



Figure 118. ¹³C NMR spectrum of the compound 6 in CDCl₃, 100 MHz



Figure 119. ¹H NMR spectrum of the compound 7 in CDCl₃, 400 MHz



Figure 120. ¹³C NMR spectrum of the compound 7 in CDCl₃, 100 MHz



Figure 121. ¹H NMR spectrum of the compound 8 in CDCl₃, 400 MHz



Figure 122. ¹³C NMR spectrum of the compound 8 in CDCl₃, 100 MHz



Figure 123. ¹H NMR spectrum of the compound 9 in CDCl₃, 400 MHz



Figure 124. ¹³C NMR spectrum of the compound 9 in CDCl₃, 100 MHz



Figure S125. ¹H NMR spectrum of the compound 10 in CDCl₃, 400 MHz



Figure S126. ¹³C NMR spectrum of the compound 10 in CDCl₃, 100 MHz



Figure S127. ¹H NMR spectrum of the compound 11 in CDCl₃, 400 MHz



Figure S128. ¹³C NMR spectrum of the compound 11 in CDCl₃, 100 MHz



Figure S129. ¹H NMR spectrum of the compound 12 in CDCl₃, 400 MHz



Figure S130. ¹³C NMR spectrum of the compound 12 in CDCl₃, 100 MHz



9. 2D-NOESY proton NMR spectra of compound 4xa-1, 4xa-2 and ¹H NOESY correlations

Figure S131. 2D NOESY spectrum of the compound 4xa-1 in CDCl₃



Figure S132. 2D NOESY spectrum of the compound 4xa-2 in CDCl₃